

# ABELCET

---

## Products Affected

- ABELCET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to the formulary alternative: conventional Amphotericin B.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ABILIFY MAINTENA

## Products Affected

- ABILIFY ASIMTUFI  
INTRAMUSCULAR  
SUSPENSION,EXTENDED REL  
SYRING 720 MG/2.4 ML, 960 MG/3.2  
ML
  - ABILIFY MAINTENA  
INTRAMUSCULAR
- SUSPENSION,EXTENDED REL  
RECON 300 MG, 400 MG
  - ABILIFY MAINTENA  
INTRAMUSCULAR  
SUSPENSION,EXTENDED REL  
SYRING

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented history of receiving oral aripiprazole without any clinically significant side effects.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: Invega Sustenna, Invega Trinza or Risperdal Consta.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACITRETIN

---

## Products Affected

- *acitretin*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: calcipotriene, clobetasol, cyclosporine, fluocinonide, methotrexate, or Tazorac.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACTIMMUNE

---

## Products Affected

- ACTIMMUNE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Endocrinologist, Hematologist, Infectious Disease specialist, Immunologist, Oncologist, Orthopedist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADEFOVIR

---

## Products Affected

- *adefovir*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Hepatologist, Infectious Disease specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADHD

## Products Affected

- *dexmethylphenidate oral tablet*
- *methylphenidate hcl oral capsule, er biphasic 30-70*
- *methylphenidate hcl oral capsule, er biphasic 50-50*
- *methylphenidate hcl oral solution*
- *methylphenidate hcl oral tablet*
- *methylphenidate hcl oral tablet extended release*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AIMOVIG

---

## Products Affected

- AIMOVIG AUTOINJECTOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist, Headache Specialist, Pain Specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to one of the formulary alternatives: divalproex, valproic acid, or topiramate and failure or clinically significant adverse effects to one of the formulary alternatives: metoprolol, timolol, propranolol.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ALOSETRON

---

## Products Affected

- *alosetron*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Irritable bowel syndrome with diarrhea: Failure or clinically significant adverse effects to the formulary alternative: loperamide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# AMBISOME

---

## Products Affected

- AMBISOME
- *amphotericin b liposome*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to the formulary alternative: conventional Amphotericin B.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# AMITRIPTYLINE

## Products Affected

- *amitriptyline*
- *amitriptyline-chlordiazepoxide oral tablet*  
*12.5-5 mg, 25-10 mg*
- *perphenazine-amitriptyline*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AMOXAPINE

## Products Affected

- *amoxapine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AMPHOTERICIN B

---

## Products Affected

- *amphotericin b*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Subject to Part B vs Part D determination.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# ANTICONVULSANTS 1

## Products Affected

- APTIOM ORAL TABLET 200 MG, 400 MG, 600 MG, 800 MG
- EPIDIOLEX
- FYCOMPA ORAL SUSPENSION
- FYCOMPA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to one of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid or zonisamide.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# ANTICONVULSANTS 2

**Products Affected**

- *clobazam oral suspension*
- *clobazam oral tablet*
- DIACOMIT
- FINTEPLA
- MOTPOLY XR ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 150 MG, 200 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Clobazam, Fenfluramine, or Stiripentol: Must be used as adjunctive treatment of seizure. Lacosamide: For partial seizure: Failure or clinically significant adverse effects to two of the following: carbamazepine, divalproex, felbamate, gabapentin, levetiracetam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid or zonisamide. For tonic-clonic seizure: Failure or clinically significant adverse effects to two of the following: lamotrigine, levetiracetam, phenytoin, or topiramate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ANTINEOPLASTIC

---

## Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG
- AKEEGA
- ALECENSA
- ALUNBRIG
- AUGTYRO ORAL CAPSULE 40 MG
- AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG
- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG
- BESREMI
- BOSULIF
- BRAFTOVI
- BRUKINSA
- CABOMETYX
- CALQUENCE (ACALABRUTINIB MAL)
- CAPRELSA
- COMETRIQ
- COPIKTRA
- COTELLIC
- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*
- DAURISMO ORAL TABLET 100 MG, 25 MG
- ERIVEDGE
- ERLEADA ORAL TABLET 240 MG, 60 MG
- *erlotinib oral tablet 100 mg, 150 mg, 25 mg*
- *everolimus (antineoplastic) oral tablet*
- *everolimus (antineoplastic) oral tablet for suspension 3 mg, 5 mg*
- EXKIVITY
- FOTIVDA
- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG
- GAVRETO
- *gefitinib*
- GILOTRIF
- GLEOSTINE
- IBRANCE
- ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG
- IDHIFA
- *imatinib oral tablet 100 mg, 400 mg*
- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG
- INLYTA ORAL TABLET 1 MG, 5 MG
- INQOVI
- INREBIC
- IRESSA
- ITOVEBI ORAL TABLET 3 MG, 9 MG
- IWILFIN
- JAKAFI
- JAYPIRCA ORAL TABLET 100 MG, 50 MG
- KISQALI FEMARA CO-PACK
- KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)
- KOSELUGO ORAL CAPSULE 10 MG, 25 MG
- KRAZATI
- *lapatinib*
- LAZCLUZE ORAL TABLET 240 MG, 80 MG
- *lenalidomide*
- LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY (10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X 2), 20 MG/DAY (10 MG X 2), 24 MG/DAY (10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)
- LONSURF
- LORBRENA ORAL TABLET 100 MG, 25 MG
- LUMAKRAS ORAL TABLET 120 MG, 320 MG

- LYNPARZA
- LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)
- MATULANE
- MEKINIST ORAL RECON SOLN
- MEKINIST ORAL TABLET 0.5 MG, 2 MG
- MEKTOVI
- NERLYNX
- NEXAVAR
- NINLARO
- NUBEQA
- ODOMZO
- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG
- OJEMDA ORAL SUSPENSION FOR RECONSTITUTION
- OJEMDA ORAL TABLET
- OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG
- ONUREG
- ORGOVYX
- ORSERDU ORAL TABLET 345 MG, 86 MG
- PANRETIN
- *pazopanib*
- PEMAZYRE
- PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)
- POMALYST
- PURIXAN
- QINLOCK
- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG
- REVLIMID
- REZLIDHIA
- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PELLETS IN PACKET
- RUBRACA
- RYDAPT
- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG
- *sorafenib*
- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG
- STIVARGA
- *sunitinib malate*
- SUTENT
- TABLOID
- TABRECTA
- TAFINLAR
- TAGRISSO
- TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG
- TASIGNA
- TAZVERIK
- TEPMETKO
- THALOMID
- TIBSOVO
- *torpenz*
- TRUQAP
- TUKYSA ORAL TABLET 150 MG, 50 MG
- TURALIO ORAL CAPSULE 125 MG, 200 MG
- VANFLYTA
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION
- VIZIMPRO
- VONJO
- VORANIGO ORAL TABLET 10 MG, 40 MG
- VOTRIENT
- WELIREG
- XALKORI ORAL CAPSULE
- XALKORI ORAL PELLETS 150 MG, 20 MG, 50 MG
- XERMELO
- XOSPATA



- XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)
- XTANDI
- YONSA
- ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# APREPITANT

---

## Products Affected

- *aprepitant*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 months.
Other Criteria	Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to one of the formulary 5-HT3 antagonist alternatives: ondansetron or granisetron except when the member is on any chemotherapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# ARCALYST

---

## Products Affected

- ARCALYST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concurrently taking any tumor necrosis factor (TNF)-blocking agents such as Enbrel, Humira, or Remicade.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ARIKAYCE

---

## Products Affected

- ARIKAYCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation: positive sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ARMODAFINIL

---

## Products Affected

- *armodafinil*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Narcolepsy: Failure or clinically significant adverse effects to all of the formulary alternatives: dextroamphetamine and methylphenidate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ATOVAQUONE

---

## Products Affected

- *atovaquone*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Pneumocystic pneumonia: Failure or clinically significant adverse effects to the formulary alternative: trimethoprim/sulfamethoxazole.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AUBAGIO

---

**Products Affected**

- AUBAGIO
- *teriflunomide*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AUSTEDO

---

## Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concurrent use with an MAOI. Untreated or inadequately-treated depression, or current suicidality in patients with Huntington disease.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist, Psychiatrist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Chorea (Huntington's Disease): Failure or clinically significant adverse effects to the formulary alternative: tetrabenazine. Reauthorization only: Documentation of positive response to medication therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# AUVELITY

---

## Products Affected

- AUVELITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# BRONCHITOL

---

## Products Affected

- BRONCHITOL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	New: Documentation that patient has passed the BRONCHITOL Tolerance Test (BTT). Reauthorization only: Documentation of positive response to medication therapy (improvement in lung function as determined by change in FEV1).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CASPOFUNGIN

---

## Products Affected

- *caspofungin*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# CIMZIA

## Products Affected

- CIMZIA
- CIMZIA POWDER FOR RECONST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Rheumatologist, Dermatologist, or Gastroenterologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Rheumatoid Arthritis: Failure or clinically significant adverse effects to two of the formulary alternatives: Enbrel, Humira, Rinvoq, or Xeljanz IR/XR. Crohn's Disease: Failure or clinically significant adverse effects to two of the formulary alternatives: Humira, Stelara, or Skyrizi. Psoriatic arthritis: Failure or clinically significant adverse effects to two of the formulary alternatives: Enbrel, Humira, Stelara, Xeljanz IR/XR, Rinvoq, or Skyrizi. Ankylosing spondylitis: Failure or clinically significant adverse effects to two of the formulary alternatives: Enbrel, Humira, Rinvoq, or Xeljanz IR/XR. Non-radiographic Axial Spondyloarthritis: Failure or clinically significant adverse effects to the formulary alternative: Cosentyx. Plaque psoriasis: Failure or clinically significant adverse effects to two of the formulary alternatives: Humira, Stelara, Enbrel, or Skyrizi.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CLOMIPRAMINE

## Products Affected

- *clomipramine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Any of the following: Concomitant use of an MAOI, or Use within 14 days of discontinuing an MAOI, or Concomitant use of linezolid, or Concomitant use of intravenous methylene blue, or Use during the acute recovery period after a myocardial infarction.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Obsessive-Compulsive Disorder: Failure or clinically significant adverse effects to two of the formulary alternatives: fluoxetine, fluvoxamine, or sertraline.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CONSTIPATION AGENTS

---

## Products Affected

- MOVANTIK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to one of the formulary alternatives: lactulose or polyethylene glycol.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# CORLANOR

## Products Affected

- CORLANOR ORAL SOLUTION                      • *ivabradine*
- CORLANOR ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Heart failure in adult patients: Documented New York Association (NYHA) class II to IV heart failure with an ejection fraction of less than or equal to 35% and sinus rhythm with a resting heart rate greater than or equal to 70 beats per minute (bpm). Documentation that patient is on maximally tolerated dose of beta blocker or has a history of a documented intolerance, contraindication or a hypersensitivity to beta blocker. Documented concurrent use with an ACE inhibitor or ARB, unless both are not tolerated or contraindicated. Heart failure in pediatric patients: Documented NYHA/Ross class II to IV heart failure with an ejection fraction of less than or equal to 45% and sinus rhythm with a resting heart rate greater than or equal to 105 bpm in the age subset 6-12 months, greater than or equal to 95 bpm in the age subset 1-3 years, greater than or equal to 75 bpm in the age subset 3-5 years, greater than or equal to 70 bpm in the age subset 5-18 years</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Cardiologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# COSENTYX

## Products Affected

- COSENTYX (2 SYRINGES)
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML
- COSENTYX UNOREADY PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Ankylosing spondylitis: For adults, failure or clinically significant adverse effects to both of the formulary alternatives: Enbrel and Humira. Psoriatic arthritis: For adults, failure or clinically significant adverse effects to both of the formulary alternatives: Enbrel and Humira. Plaque Psoriasis: For adults, failure or clinically significant adverse effects to one of the formulary alternatives: Humira, Enbrel, or Skyrizi. Non-radiographic Axial Spondyloarthritis: Failure or clinically significant adverse effects to a non-steroidal anti-inflammatory drug (NSAID) or has an intolerance or contraindication to NSAID.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# CYCLOBENZAPRINE

---

## Products Affected

- *cyclobenzaprine oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Documentation explaining specific benefit established with the medication, and how that benefit outweighs the potential risk
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DALFAMPRIDINE

---

## Products Affected

- *dalfampridine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Moderate or severe renal impairment (CrCL 50 mL/min or less).
<b>Required Medical Information</b>	Concurrently on a disease-modifying agent for multiple sclerosis. Documentation of difficulty walking (such as timed 25-foot walk test: Patient must be able to walk 25 feet within 8-45 sec). Reauthorization only: Documentation of positive response to medication therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DALIRESP

---

## Products Affected

- DALIRESP
- *roflumilast*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Liver impairment, moderate to severe (Child-Pugh B or C).
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: either Wixela or Fluticasone/Salmeterol, Anoro Ellipta, Serevent, Spiriva or Tudorza.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DEFERASIROX

---

## Products Affected

- *deferasirox oral tablet, dispersible*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DESIPRAMINE

---

## Products Affected

- *desipramine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# DIAZEPAM SOLUTION

## Products Affected

- *diazepam intensol*
- *diazepam oral solution 5 mg/5 ml (1 mg/ml)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of difficulty or inability to swallow.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DIMETHYL FUMARATE

---

## Products Affected

- *dimethyl fumarate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: Aubagio and glatiramer.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DISOPYRAMIDE

## Products Affected

- *disopyramide phosphate oral capsule*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Arrhythmia: Failure or clinically significant adverse effects to two of the formulary alternatives: acebutolol, flecainide, mexiletine, propafenone, quinidine, or sotalol.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# DOXEPIN

## Products Affected

- *doxepin oral capsule*
- *doxepin oral concentrate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	For the average daily dose of doxepin that is greater than 6 mg: Anxiety: Failure or clinically significant adverse effects to two of the formulary alternatives: buspirone, duloxetine, escitalopram, or venlafaxine. Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DRIZALMA

---

## Products Affected

- DRIZALMA SPRINKLE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of difficulty or inability to swallow an intact capsule or failure or clinically significant adverse effects to the formulary alternative: duloxetine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DRONABINOL

## Products Affected

- *dronabinol*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Chemotherapy-induced nausea and vomiting: Failure or clinically significant adverse effects to two of the formulary alternatives: chlorpromazine, granisetron, metoclopramide, ondansetron, or prochlorperazine.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# DROXIDOPA

---

## Products Affected

- *droxidopa*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DUPIXENT

## Products Affected

- DUPIXENT PEN
- DUPIXENT SYRINGE  
SUBCUTANEOUS SYRINGE 200  
MG/1.14 ML, 300 MG/2 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Initial: eosinophilic asthma: blood eosinophil level greater than or equal to 150 cells/mcl within the past 12 months. Eosinophilic Esophagitis: diagnosis confirmed by esophagogastroduodenoscopy with biopsy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Initial: Atopic Dermatitis, Prurigo Nodularis: prescribed by or in consultation with a Dermatologist, Allergist or Immunologist. Asthma: prescribed by or in consultation with a physician specializing in allergy or pulmonary medicine. Chronic Rhinosinusitis with Nasal Polyposis: prescribed by or in consultation with an Otolaryngologist, Allergist or Immunologist. Eosinophilic Esophagitis: prescribed by or in consultation with a Gastroenterologist, Allergist, or Immunologist.
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Initial: Atopic Dermatitis: 1) Atopic Dermatitis covering at least 10 percent of body surface area or Atopic Dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas, 2) intractable pruritus or cracking/oozing/bleeding of affected skin, 3) trial of or contraindication to one topical (corticosteroid or calcineurin inhibitor), and 4) no concurrent use with other systemic biologic/JAK inhibitor for Atopic Dermatitis. Asthma: 1) concurrent therapy with a medium, high-dose or maximally-tolerated dose of an inhaled corticosteroid (ICS) and one other maintenance medication, 2) one asthma exacerbation requiring systemic corticosteroid burst lasting 3 or more days within the past 12 months, or one serious exacerbation requiring hospitalization or ER visit within the past 12 months, or poor symptom control despite current therapy as evidenced by at least three of the following within the past 4 weeks: daytime asthma symptoms more than twice/week, any night waking due to asthma, Short-Acting Beta Agonist (SABA) reliever for symptoms more than twice/week, any activity limitation due to asthma, and 3) no concurrent use with Xolair or other Anti-IL5 biologics when used for

PA Criteria	Criteria Details
	<p>asthma. Chronic Rhinosinusitis with Nasal Polyposis: 1) evidence of nasal polyps by direct examination, endoscopy or sinus CT scan, 2) inadequately controlled disease as determined by use of systemic steroids in the past 2 years or endoscopic sinus surgery, and 3) trial of one topical nasal corticosteroid. Prurigo Nodularis: 1) chronic pruritis (itch more than 6 weeks), multiple pruriginous lesions, and history or sign of a prolonged scratching behavior, 2) trial of or contraindication to one topical (corticosteroid or calcipotriene). Renewal: Atopic Dermatitis: 1) improvement while on therapy, and 2) no concurrent use with other systemic biologic/JAK inhibitor for Atopic Dermatitis. Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis: improvement while on therapy. Asthma: 1) no concurrent use with Xolair, or other Anti-IL5 biologics for asthma, 2) continued use of ICS and one other maintenance medication, and 3) clinical response as evidenced by: (a) reduction in asthma exacerbations from baseline, (b) decreased utilization of rescue medications, (c) increase in percent predicted FEV1 from pretreatment baseline, or (d) reduction in severity or frequency of asthma-related symptoms. Prurigo Nodularis: improvement or reduction of pruritis or pruriginous lesions.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ELIGARD

---

## Products Affected

- ELIGARD
- ELIGARD (3 MONTH)
- ELIGARD (4 MONTH)
- ELIGARD (6 MONTH)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Oncologist, Urologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EMSAM

---

## Products Affected

- EMSAM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use with other serotonergic drugs (i.e. SSRIs, SNRIs, TCAs)
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: phenelzine and tranylcypromine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ENBREL

## Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
- ENBREL SURECLICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Plaque psoriasis: Failure or clinically significant adverse effects to one of the following: acitretin, cyclosporine, methotrexate or phototherapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENDARI

---

## Products Affected

- ENDARI
- *glutamine (sickle cell)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Hematologist
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# ESBRIET

## Products Affected

- ESBRIET ORAL CAPSULE
- ESBRIET ORAL TABLET 267 MG, 801 MG
- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Initial authorization: Diagnosis of idiopathic pulmonary fibrosis confirmed by the presence of usual interstitial pneumonia on high resolution computed tomography (HRCT) and/or surgical lung biopsy. Documentation of liver function tests, documentation of baseline forced vital capacity (FVC) greater than or equal to 50 percent of the predicted value AND documentation of percent predicted diffusing capacity of the lungs for carbon monoxide (%DLCO) greater than or equal to 30 percent.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ESTROGENS

## Products Affected

- DUAVEE
- *estradiol oral*
- *estradiol transdermal patch weekly*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Postmenopausal osteoporosis prophylaxis: Failure or clinically significant adverse effects all of the formulary alternatives: alendronic acid and risedronate. Vulvar and vaginal atrophy: Failure or clinically significant adverse effects to one of the formulary alternatives: estradiol cream or Premarin Cream.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FENTANYL LOZENGE

## Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Acute, intermittent, or postoperative pain.
<b>Required Medical Information</b>	Documentation of opioid tolerance taking around-the-clock opioid therapy consisting of at least 60mg of oral morphine daily, at least 25mg transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least 8mg oral hydromorphone daily or an equianalgesic dose of another opioid daily for a week or longer for breakthrough pain of cancer. Patients must remain on around-the clock opioids when taking transmucosal immediate release fentanyl.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Pain Specialist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FETZIMA

## Products Affected

- FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26)
- FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FIRAZYR

---

## Products Affected

- *icatibant*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of hereditary angioedema (HAE), must be confirmed by blood testing.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Allergist, Immunologist, Hematologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FIRMAGON

---

## Products Affected

- FIRMAGON KIT W DILUENT SYRINGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Oncologist, Urologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# GENOTROPIN

## Products Affected

- GENOTROPIN
- GENOTROPIN MINIQUICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	AGHD(initial): diagnosis confirmed as a result of past diagnosis of childhood-onset GHD, or adult-onset GHD with documentation of hormone deficiency due to hypothalamic-pituitary disease from organic or known causes (eg: damage from surgery, cranial irradiation, head trauma, subarachnoid hemorrhage) and documentation of one growth-hormone stimulant test (eg: insulin tolerance test, arginine/GHRH,glucagon,arginine) to confirm adult GHD w/corresponding peak GH values ([ITT at or below 5mcg/L],[GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2],[glucagon at or below 3mcg/L],[Arg at or below 0.4mcg/L]) or documented deficiency of 3 anterior pituitary hormones (prolactin,ACTH,TSH,FSH/LH) and IFG-1/somatomedinC below age and gender adjusted normal range as provided by physicians lab. AGHD(reauthorization): Documentation of positive experience by the patient.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GEODON SOLUTION

---

## Products Affected

- *ziprasidone mesylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# GILENYA

## Products Affected

- *fingolimod*
- GILENYA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Class III or IV heart failure, decompensated heart failure requiring hospitalization, myocardial infarction, stroke, transient ischemic attack or unstable angina within the last 6 months. Concomitant use of Class Ia or Class III anti-arrhythmic drugs. Mobitz type II second-degree or third-degree atrioventricular block, or sick-sinus syndrome unless the patient has a functional pacemaker. QT interval at baseline 500 ms or greater.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	For adults: Failure or clinically significant adverse effects to Aubagio and glatiramer.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GLATIRAMER

---

## Products Affected

- *glatiramer*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GLATOPA

---

## Products Affected

- *glatopa*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# GLP1

## Products Affected

- MOUNJARO MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2
- OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/DOSE (8 MG/3 ML)
- RYBELSUS
- TRULICITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or a personal or family history of medullary thyroid carcinoma (MTC), treatment for obesity or weight loss only, and concurrent use with DPP4 inhibitors.
<b>Required Medical Information</b>	For a diagnosis of Type 2 Diabetes Mellitus the patient has a trial and failure, contraindication or intolerance to metformin or any metformin combination product.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Reauthorization only: Documentation of positive response to medication therapy (reduction in HbA1C or maintenance of HbA1c level).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GLYBURIDE

## Products Affected

- *glyburide*
- *glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg*
- *glyburide micronized*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to formulary alternative: glipizide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GUANFACINE

## Products Affected

- *guanfacine oral tablet*
- *guanfacine oral tablet extended release 24 hr*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Hypertension: Failure or clinically significant adverse effects to two of the formulary alternatives: benazepril, fosinopril, hydrochlorothiazide, irbesartan, lisinopril, losartan, losartan/hydrochlorothiazide, lisinopril/hydrochlorothiazide, quinapril/hydrochlorothiazide, quinapril, ramipril, or valsartan/hydrochlorothiazide. ADHD: Failure or clinically significant adverse effects to two of the formulary alternatives: amphetamine/dextroamphetamine, dexamethylphenidate, dextroamphetamine, or methylphenidate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# HRM ANTIPSYCHOTICS

## Products Affected

- *molindone oral tablet 10 mg, 25 mg, 5 mg*
- *thioridazine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HUMIRA

## Products Affected

- HUMIRA PEN
- HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML
- HUMIRA(CF)
- HUMIRA(CF) PEN
- HUMIRA(CF) PEN CROHNS-UC-HS
- HUMIRA(CF) PEN PSOR-UV-ADOL HS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis involving 3% of BSA or greater, or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Gastroenterologist, Ophthalmologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy. Crohn's disease and Ulcerative colitis: Failure or clinically significant adverse effects to one of the formulary alternatives: budesonide, mesalamine or sulfasalazine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HUMIRA PEDIATRIC

## Products Affected

- HUMIRA(CF) PEDI CROHNS STARTER
- HUMIRA(CF) PEN PEDIATRIC UC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# IMIPRAMINE

---

## Products Affected

- *imipramine hcl*
- *imipramine pamoate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# IMPAVIDO

---

## Products Affected

- IMPAVIDO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Females of Reproductive Potential: confirm negative pregnancy status.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INCRELEX

---

## Products Affected

- INCRELEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Pediatric patients with malignant neoplasm or history of malignancy. Use for growth promotion in patients with closed epiphyses.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INDOMETHACIN

---

## Products Affected

- *indomethacin oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: celecoxib, diclofenac, ibuprofen, meloxicam, nabumetone, naproxen, or sulindac.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# INGREZZA

## Products Affected

- INGREZZA
- INGREZZA INITIATION PK(TARDIV)
- INGREZZA SPRINKLE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist, Psychiatrist
Coverage Duration	Until the end of calendar year.
Other Criteria	Chorea (Huntington's Disease): Failure or clinically significant adverse effects to the formulary alternative: tetrabenazine. Reauthorization only: Documentation of positive response to medication therapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



# INSULIN SUPPLIES PAYMENT DETERMINATION

---

## Products Affected

- 1ST TIER UNIFINE PENTP 5MM 31G
- 1ST TIER UNIFINE PNTIP 4MM 32G
- 1ST TIER UNIFINE PNTIP 6MM 31G
- 1ST TIER UNIFINE PNTIP 8MM 31G STRL,SINGLE-USE,SHRT
- 1ST TIER UNIFINE PNTIP 29GX1/2"
- 1ST TIER UNIFINE PNTIP 31GX3/16
- 1ST TIER UNIFINE PNTIP 32GX5/32
- ABOUTTIME PEN NEEDLE 30G X 8MM
- ABOUTTIME PEN NEEDLE 31G X 5MM
- ABOUTTIME PEN NEEDLE 31G X 8MM
- ABOUTTIME PEN NEEDLE 32G X 4MM
- ADVOCATE INS 0.3 ML 30GX5/16"
- ADVOCATE INS 0.3 ML 31GX5/16"
- ADVOCATE INS 0.5 ML 30GX5/16"
- ADVOCATE INS 0.5 ML 31GX5/16"
- ADVOCATE INS 1 ML 31GX5/16"
- ADVOCATE INS SYR 0.3 ML 29GX1/2
- ADVOCATE INS SYR 0.5 ML 29GX1/2
- ADVOCATE INS SYR 1 ML 29GX1/2"
- ADVOCATE INS SYR 1 ML 30GX5/16
- ADVOCATE PEN NDL 12.7MM 29G
- ADVOCATE PEN NEEDLE 32G 4MM
- ADVOCATE PEN NEEDLE 4MM 33G
- ADVOCATE PEN NEEDLES 5MM 31G
- ADVOCATE PEN NEEDLES 8MM 31G
- ALCOHOL 70% SWABS
- ALCOHOL PADS
- ALCOHOL PREP SWABS
- ALCOHOL WIPES
- AQINJECT PEN NEEDLE 31G 5MM
- AQINJECT PEN NEEDLE 32G 4MM
- ASSURE ID DUO PRO NDL 31G 5MM
- ASSURE ID DUO-SHIELD 30GX3/16"
- ASSURE ID DUO-SHIELD 30GX5/16"
- ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"
- ASSURE ID PEN NEEDLE 30GX3/16"
- ASSURE ID PEN NEEDLE 30GX5/16"
- ASSURE ID PEN NEEDLE 31GX3/16"
- ASSURE ID PRO PEN NDL 30G 5MM
- ASSURE ID SYR 0.5 ML 29GX1/2" (RX)
- ASSURE ID SYR 0.5 ML 31GX15/64"
- ASSURE ID SYR 1 ML 31GX15/64"
- BD AUTOSHIELD DUO NDL 5MMX30G
- BD ECLIPSE 30GX1/2" SYRINGE
- BD ECLIPSE NEEDLE 30GX1/2" (OTC)
- BD INS SYR 0.3 ML 8MMX31G(1/2)
- BD INS SYRINGE 1/2 ML 6MMX31G (ONLY FOR 500 UNIT/ML INSULIN)
- BD INS SYRN UF 1 ML 12.7MMX30G NOT FOR RETAIL SALE
- BD INSULIN SYR 1 ML 25GX1"
- BD INSULIN SYR 1 ML 25GX5/8"
- BD INSULIN SYR 1 ML 26GX1/2"
- BD INSULIN SYR 1 ML 27GX12.7MM
- BD INSULIN SYR 1 ML 27GX5/8" MICRO-FINE
- BD INSULIN SYRINGE 1 ML W/O NEEDLE
- BD LUER-LOK SYRINGE 1 ML
- BD NANO 2 GEN PEN NDL 32G 4MM
- BD SAFETGLD INS 0.3 ML 29G 13MM
- BD SAFETGLD INS 0.5 ML 13MMX29G
- BD SAFETYGLD INS 0.3 ML 31G 8MM
- BD SAFETYGLD INS 0.5 ML 30G 8MM
- BD SAFETYGLD INS 1 ML 29G 13MM
- BD SAFETYGLID INS 1 ML 6MMX31G
- BD SAFETYGLIDE SYRINGE 27GX5/8
- BD SAFTYGLD INS 0.3 ML 6MMX31G
- BD SAFTYGLD INS 0.5 ML 29G 13MM
- BD SAFTYGLD INS 0.5 ML 6MMX31G

- BD SINGLE USE SWAB
- BD UF MICRO PEN NEEDLE 6MMX32G
- BD UF MINI PEN NEEDLE 5MMX31G
- BD UF NANO PEN NEEDLE 4MMX32G
- BD UF ORIG PEN NDL 12.7MMX29G
- BD UF SHORT PEN NEEDLE 8MMX31G
- BD VEO INS 0.3 ML 6MMX31G (1/2)
- BD VEO INS SYRING 1 ML 6MMX31G
- BD VEO INS SYRN 0.3 ML 6MMX31G
- BD VEO INS SYRN 0.5 ML 6MMX31G
- BORDERED GAUZE 2"X2"
- CAREFINE PEN NEEDLE 12.7MM 29G
- CAREFINE PEN NEEDLE 4MM 32G
- CAREFINE PEN NEEDLE 5MM 32G
- CAREFINE PEN NEEDLE 6MM 31G
- CAREFINE PEN NEEDLE 8MM 30G
- CAREFINE PEN NEEDLES 6MM 32G
- CAREFINE PEN NEEDLES 8MM 31G
- CARETOUCH ALCOHOL 70% PREP PAD
- CARETOUCH PEN NEEDLE 29G 12MM
- CARETOUCH PEN NEEDLE 31GX1/4"
- CARETOUCH PEN NEEDLE 31GX3/16"
- CARETOUCH PEN NEEDLE 31GX5/16"
- CARETOUCH PEN NEEDLE 32GX3/16"
- CARETOUCH PEN NEEDLE 32GX5/32"
- CARETOUCH SYR 0.3 ML 31GX5/16"
- CARETOUCH SYR 0.5 ML 30GX5/16"
- CARETOUCH SYR 0.5 ML 31GX5/16"
- CARETOUCH SYR 1 ML 28GX5/16"
- CARETOUCH SYR 1 ML 29GX5/16"
- CARETOUCH SYR 1 ML 30GX5/16"
- CARETOUCH SYR 1 ML 31GX5/16"
- CLICKFINE 31G X 5/16" NEEDLES 8MM, UNIVERSAL
- CLICKFINE PEN NEEDLE 32GX5/32" 32GX4MM, STERILE
- CLICKFINE UNIVERSAL 31G X 1/4" 6MM, STORE BRAND
- COMFORT EZ 0.3 ML 31G 15/64"
- COMFORT EZ 0.5 ML 31G 15/64"
- COMFORT EZ INS 0.3 ML 30GX1/2"
- COMFORT EZ INS 0.3 ML 30GX5/16"
- COMFORT EZ INS 1 ML 31G 15/64"
- COMFORT EZ INS 1 ML 31GX5/16"
- COMFORT EZ INSULIN SYR 0.3 ML
- COMFORT EZ INSULIN SYR 0.5 ML
- COMFORT EZ PEN NEEDLE 12MM 29G
- COMFORT EZ PEN NEEDLES 4MM 32G SINGLE USE, MICRO
- COMFORT EZ PEN NEEDLES 4MM 33G
- COMFORT EZ PEN NEEDLES 5MM 31G MINI
- COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI
- COMFORT EZ PEN NEEDLES 5MM 33G
- COMFORT EZ PEN NEEDLES 6MM 31G
- COMFORT EZ PEN NEEDLES 6MM 32G
- COMFORT EZ PEN NEEDLES 6MM 33G
- COMFORT EZ PEN NEEDLES 8MM 31G SHORT
- COMFORT EZ PEN NEEDLES 8MM 32G
- COMFORT EZ PEN NEEDLES 8MM 33G
- COMFORT EZ PRO PEN NDL 30G 8MM
- COMFORT EZ PRO PEN NDL 31G 4MM
- COMFORT EZ PRO PEN NDL 31G 5MM
- COMFORT EZ SYR 0.3 ML 29GX1/2"
- COMFORT EZ SYR 0.5 ML 28GX1/2"
- COMFORT EZ SYR 0.5 ML 29GX1/2"
- COMFORT EZ SYR 0.5 ML 30GX1/2"
- COMFORT EZ SYR 1 ML 28GX1/2"
- COMFORT EZ SYR 1 ML 29GX1/2"

- COMFORT EZ SYR 1 ML 30GX1/2"
- COMFORT EZ SYR 1 ML 30GX5/16"
- COMFORT POINT PEN NDL 31GX1/3"
- COMFORT POINT PEN NDL 31GX1/6"
- COMFORT TOUCH PEN NDL 31G 4MM
- COMFORT TOUCH PEN NDL 31G 5MM
- COMFORT TOUCH PEN NDL 31G 6MM
- COMFORT TOUCH PEN NDL 31G 8MM
- COMFORT TOUCH PEN NDL 32G 4MM
- COMFORT TOUCH PEN NDL 32G 5MM
- COMFORT TOUCH PEN NDL 32G 6MM
- COMFORT TOUCH PEN NDL 32G 8MM
- COMFORT TOUCH PEN NDL 33G 4MM
- COMFORT TOUCH PEN NDL 33G 6MM
- COMFORT TOUCH PEN NDL 33GX5MM
- CURAD GAUZE PADS 2" X 2"
- CURITY ALCOHOL PREPS 2 PLY,MEDIUM
- CURITY GAUZE SPONGES (12 PLY)-200/BAG
- CURITY GUAZE PADS 1'S(12 PLY)
- DERMACEA 2"X2" GAUZE 12 PLY, USP TYPE VII
- DERMACEA GAUZE 2"X2" SPONGE 8 PLY
- DERMACEA NON-WOVEN 2"X2" SPNGE
- DROPLET 0.5 ML 29GX12.5MM(1/2)
- DROPLET 0.5 ML 30GX12.5MM(1/2)
- DROPLET INS 0.3 ML 29GX12.5MM
- DROPLET INS 0.3 ML 30GX12.5MM
- DROPLET INS 0.5 ML 30GX6MM(1/2)
- DROPLET INS 0.5 ML 30GX8MM(1/2)
- DROPLET INS 0.5 ML 31GX6MM(1/2)
- DROPLET INS 0.5 ML 31GX8MM(1/2)
- DROPLET INS SYR 0.3 ML 30GX6MM
- DROPLET INS SYR 0.3 ML 30GX8MM
- DROPLET INS SYR 0.3 ML 31GX6MM
- DROPLET INS SYR 0.3 ML 31GX8MM
- DROPLET INS SYR 1 ML 29GX12.5MM
- DROPLET INS SYR 1 ML 30GX12.5MM
- DROPLET INS SYR 1 ML 30GX6MM
- DROPLET INS SYR 1 ML 30GX8MM
- DROPLET INS SYR 1 ML 31GX6MM
- DROPLET INS SYR 1 ML 31GX8MM
- DROPLET MICRON 34G X 9/64"
- DROPLET PEN NEEDLE 29GX1/2"
- DROPLET PEN NEEDLE 29GX3/8"
- DROPLET PEN NEEDLE 30GX5/16"
- DROPLET PEN NEEDLE 31GX1/4"
- DROPLET PEN NEEDLE 31GX3/16"
- DROPLET PEN NEEDLE 31GX5/16"
- DROPLET PEN NEEDLE 32GX1/4"
- DROPLET PEN NEEDLE 32GX3/16"
- DROPLET PEN NEEDLE 32GX5/16"
- DROPLET PEN NEEDLE 32GX5/32"
- DROPSAFE ALCOHOL 70% PREP PADS
- DROPSAFE INS SYR 0.3 ML 31G 6MM
- DROPSAFE INS SYR 0.3 ML 31G 8MM
- DROPSAFE INS SYR 0.5 ML 31G 6MM
- DROPSAFE INS SYR 0.5 ML 31G 8MM
- DROPSAFE INSUL SYR 1 ML 31G 6MM
- DROPSAFE INSUL SYR 1 ML 31G 8MM
- DROPSAFE INSULN 1 ML 29G 12.5MM
- DROPSAFE PEN NEEDLE 31GX1/4"
- DROPSAFE PEN NEEDLE 31GX3/16"
- DROPSAFE PEN NEEDLE 31GX5/16"
- DRUG MART ULTRA COMFORT SYR
- EASY CMFT SFTY PEN NDL 31G 5MM
- EASY CMFT SFTY PEN NDL 31G 6MM
- EASY CMFT SFTY PEN NDL 32G 4MM
- EASY COMFORT 0.3 ML 31G 1/2"

- EASY COMFORT 0.3 ML 31G 5/16"
- EASY COMFORT 0.3 ML SYRINGE
- EASY COMFORT 0.5 ML 30GX1/2"
- EASY COMFORT 0.5 ML 31GX5/16"
- EASY COMFORT 0.5 ML 32GX5/16"
- EASY COMFORT 0.5 ML SYRINGE
- EASY COMFORT 1 ML 31GX5/16"
- EASY COMFORT 1 ML 32GX5/16"
- EASY COMFORT ALCOHOL 70% PAD
- EASY COMFORT INSULIN 1 ML SYR
- EASY COMFORT PEN NDL 31GX1/4"
- EASY COMFORT PEN NDL 31GX3/16"
- EASY COMFORT PEN NDL 31GX5/16"
- EASY COMFORT PEN NDL 32GX5/32"
- EASY COMFORT PEN NDL 33G 4MM
- EASY COMFORT PEN NDL 33G 5MM
- EASY COMFORT PEN NDL 33G 6MM
- EASY COMFORT SYR 1 ML 30GX1/2"
- EASY GLIDE INS 0.3 ML 31GX6MM
- EASY GLIDE INS 0.5 ML 31GX6MM
- EASY GLIDE INS 1 ML 31GX6MM
- EASY GLIDE PEN NEEDLE 4MM 33G
- EASY TOUCH 0.3 ML SYR 30GX1/2"
- EASY TOUCH 0.5 ML SYR 27GX1/2"
- EASY TOUCH 0.5 ML SYR 29GX1/2"
- EASY TOUCH 0.5 ML SYR 30GX1/2"
- EASY TOUCH 0.5 ML SYR 30GX5/16
- EASY TOUCH 1 ML SYR 27GX1/2"
- EASY TOUCH 1 ML SYR 29GX1/2"
- EASY TOUCH 1 ML SYR 30GX1/2"
- EASY TOUCH ALCOHOL 70% PADS  
GAMMA-STERILIZED
- EASY TOUCH FLIPLK 1 ML 27GX0.5
- EASY TOUCH INSULIN 1 ML 29GX1/2
- EASY TOUCH INSULIN 1 ML 30GX1/2
- EASY TOUCH INSULIN SYR 0.3 ML
- EASY TOUCH INSULIN SYR 0.5 ML
- EASY TOUCH INSULIN SYR 1 ML
- EASY TOUCH INSULIN SYR 1 ML  
RETRACTABLE
- EASY TOUCH INSULN 1 ML 29GX1/2"
- EASY TOUCH INSULN 1 ML 30GX1/2"
- EASY TOUCH INSULN 1 ML 30GX5/16
- EASY TOUCH INSULN 1 ML 31GX5/16
- EASY TOUCH LUER LOK INSUL 1 ML
- EASY TOUCH PEN NEEDLE 29GX1/2"
- EASY TOUCH PEN NEEDLE 30GX5/16
- EASY TOUCH PEN NEEDLE 31GX1/4"
- EASY TOUCH PEN NEEDLE 31GX3/16
- EASY TOUCH PEN NEEDLE 31GX5/16
- EASY TOUCH PEN NEEDLE 32GX1/4"
- EASY TOUCH PEN NEEDLE 32GX3/16
- EASY TOUCH PEN NEEDLE 32GX5/32
- EASY TOUCH SAF PEN NDL 29G  
5MM
- EASY TOUCH SAF PEN NDL 29G  
8MM
- EASY TOUCH SAF PEN NDL 30G  
5MM
- EASY TOUCH SAF PEN NDL 30G  
8MM
- EASY TOUCH SYR 0.5 ML 28G  
12.7MM
- EASY TOUCH SYR 0.5 ML 29G  
12.7MM
- EASY TOUCH SYR 1 ML 27G 16MM
- EASY TOUCH SYR 1 ML 28G 12.7MM
- EASY TOUCH SYR 1 ML 29G 12.7MM
- EASY TOUCH UNI-SLIP SYR 1 ML
- EASYTOUCH SAF PEN NDL 30G 6MM
- EMBRACE PEN NEEDLE 29G 12MM
- EMBRACE PEN NEEDLE 30G 5MM
- EMBRACE PEN NEEDLE 30G 8MM
- EMBRACE PEN NEEDLE 31G 5MM
- EMBRACE PEN NEEDLE 31G 6MM
- EMBRACE PEN NEEDLE 31G 8MM
- EMBRACE PEN NEEDLE 32G 4MM
- EQL INSULIN 0.3 ML SYRINGE  
SHORT NEEDLE
- EQL INSULIN 0.5 ML SYRINGE  
SHORT NEEDLE
- EQL INSULIN 1 ML SYRINGE SHORT  
NEEDLE
- FIFTY50 INS 0.5 ML 31GX5/16"  
SHORT NEEDLE (OTC)
- FIFTY50 INS SYR 1 ML 31GX5/16"  
SHORT NEEDLE (OTC)
- FIFTY50 PEN 31G X 3/16" NEEDLE  
(OTC)
- FP INSULIN 1 ML SYRINGE
- FREESTYLE PREC 0.5 ML 30GX5/16
- FREESTYLE PREC 0.5 ML 31GX5/16

- FREESTYLE PREC 1 ML 30GX5/16"
- FREESTYLE PREC 1 ML 31GX5/16"
- GAUZE PAD TOPICAL BANDAGE 2 X 2 "
- GNP ULT C 0.3 ML 29GX1/2" (1/2) 1/2 UNIT
- GNP ULTRA COMFORT 0.5 ML SYR
- GNP ULTRA COMFORT 1 ML SYRINGE
- GNP ULTRA COMFORT 3/10 ML SYR
- HEALTHWISE INS 0.3 ML 30GX5/16"
- HEALTHWISE INS 0.3 ML 31GX5/16"
- HEALTHWISE INS 0.5 ML 30GX5/16"
- HEALTHWISE INS 0.5 ML 31GX5/16"
- HEALTHWISE INS 1 ML 30GX5/16"
- HEALTHWISE INS 1 ML 31GX5/16"
- HEALTHWISE PEN NEEDLE 31G 5MM
- HEALTHWISE PEN NEEDLE 31G 8MM
- HEALTHWISE PEN NEEDLE 32G 4MM
- HEALTHY ACCENTS PENTIP 4MM 32G
- HEALTHY ACCENTS PENTIP 5MM 31G
- HEALTHY ACCENTS PENTIP 6MM 31G
- HEALTHY ACCENTS PENTIP 8MM 31G
- HEALTHY ACCENTS PENTIP 12MM 29G
- HEB INCONTROL ALCOHOL 70% PADS
- INCONTROL PEN NEEDLE 12MM 29G
- INCONTROL PEN NEEDLE 4MM 32G
- INCONTROL PEN NEEDLE 5MM 31G
- INCONTROL PEN NEEDLE 6MM 31G
- INCONTROL PEN NEEDLE 8MM 31G
- INSULIN SYR 0.3 ML 31GX1/4(1/2)
- INSULIN SYRIN 0.3 ML 30GX1/2" SHORT NEEDLE
- INSULIN SYRIN 0.5 ML 28GX1/2" (OTC)
- INSULIN SYRIN 0.5 ML 29GX1/2" (OTC)
- INSULIN SYRIN 0.5 ML 30GX1/2" SHORT NEEDLE (OTC)
- INSULIN SYRIN 0.5 ML 30GX5/16" SHORT NEEDLE (OTC)
- INSULIN SYRING 0.5 ML 27G 1/2" INNER (OTC)
- INSULIN SYRINGE 0.3 ML
- INSULIN SYRINGE 0.3 ML 31GX1/4
- INSULIN SYRINGE 0.5 ML
- INSULIN SYRINGE 0.5 ML 31GX1/4
- INSULIN SYRINGE 1 ML
- INSULIN SYRINGE 1 ML 27G 1/2" INNER
- INSULIN SYRINGE 1 ML 28G 1/2" INNER (RX)
- INSULIN SYRINGE 1 ML 30GX1/2" (RX)
- INSULIN SYRINGE 1 ML 30GX5/16" SHORT NEEDLE (OTC)
- INSULIN SYRINGE 1 ML 31GX1/4"
- INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE
- INSUPEN 30G ULTRAFIN NEEDLE
- INSUPEN 31G ULTRAFIN NEEDLE
- INSUPEN 32G 6MM PEN NEEDLE
- INSUPEN 32G 8MM PEN NEEDLE
- INSUPEN PEN NEEDLE 29GX12MM
- INSUPEN PEN NEEDLE 31GX3/16"
- INSUPEN PEN NEEDLE 32GX4MM
- INSUPEN PEN NEEDLE 33GX4MM
- IV ANTISEPTIC WIPES
- KENDALL ALCOHOL 70% PREP PAD
- LISCO SPONGES 100/BAG
- LITE TOUCH 31GX1/4" PEN NEEDLE
- LITE TOUCH INSULIN 0.5 ML SYR
- LITE TOUCH INSULIN 1 ML SYR
- LITE TOUCH INSULIN SYR 1 ML
- LITE TOUCH PEN NEEDLE 29G
- LITE TOUCH PEN NEEDLE 31G
- LITETOUCH INS 0.3 ML 29GX1/2"
- LITETOUCH INS 0.3 ML 30GX5/16"
- LITETOUCH INS 0.3 ML 31GX5/16"
- LITETOUCH INS 0.5 ML 31GX5/16"
- LITETOUCH SYR 0.5 ML 28GX1/2"
- LITETOUCH SYR 0.5 ML 29GX1/2"

- LITETOUCH SYR 0.5 ML 30GX5/16"
- LITETOUCH SYRIN 1 ML 28GX1/2"
- LITETOUCH SYRIN 1 ML 29GX1/2"
- LITETOUCH SYRIN 1 ML 30GX5/16"
- MAGELLAN INSUL SYRINGE 0.3 ML
- MAGELLAN INSUL SYRINGE 0.5 ML
- MAGELLAN INSULIN SYR 0.3 ML
- MAGELLAN INSULIN SYR 0.5 ML
- MAGELLAN INSULIN SYRINGE 1 ML
- MAXI-COMFORT INS 0.5 ML 28G
- MAXI-COMFORT INS 1 ML 28GX1/2"
- MAXICOMFORT II PEN NDL 31GX6MM
- MAXICOMFORT INS 0.5 ML 27GX1/2"
- MAXICOMFORT INS 1 ML 27GX1/2"
- MAXICOMFORT PEN NDL 29G X 5MM
- MAXICOMFORT PEN NDL 29G X 8MM
- MICRODOT PEN NEEDLE 31GX6MM
- MICRODOT PEN NEEDLE 32GX4MM
- MICRODOT PEN NEEDLE 33GX4MM
- MICRODOT READYGARD NDL 31G 5MM OUTER
- MINI PEN NEEDLE 32G 4MM
- MINI PEN NEEDLE 32G 5MM
- MINI PEN NEEDLE 32G 6MM
- MINI PEN NEEDLE 32G 8MM
- MINI PEN NEEDLE 33G 4MM
- MINI PEN NEEDLE 33G 5MM
- MINI PEN NEEDLE 33G 6MM
- MINI ULTRA-THIN II PEN NDL 31G STERILE
- MONOJECT 0.5 ML SYRN 28GX1/2"
- MONOJECT 1 ML SYRN 27X1/2"
- MONOJECT 1 ML SYRN 28GX1/2" (OTC)
- MONOJECT INSUL SYR U100 (OTC)
- MONOJECT INSUL SYR U100 .5ML,29GX1/2" (OTC)
- MONOJECT INSUL SYR U100 0.5 ML CONVERTS TO 29G (OTC)
- MONOJECT INSUL SYR U100 1 ML
- MONOJECT INSUL SYR U100 1 ML 3'S, 29GX1/2" (OTC)
- MONOJECT INSUL SYR U100 1 ML W/O NEEDLE (OTC)
- MONOJECT INSULIN SYR 0.3 ML
- MONOJECT INSULIN SYR 0.3 ML (OTC)
- MONOJECT INSULIN SYR 0.5 ML
- MONOJECT INSULIN SYR 0.5 ML (OTC)
- MONOJECT INSULIN SYR 1 ML 3'S (OTC)
- MONOJECT INSULIN SYR U-100
- MONOJECT SYRINGE 0.3 ML
- MONOJECT SYRINGE 0.5 ML
- MONOJECT SYRINGE 1 ML
- NOVOFINE 30
- NOVOFINE 32G NEEDLES
- NOVOFINE PLUS PEN NDL 32GX1/6"
- NOVOTWIST NEEDLE 32G 5MM
- PC UNIFINE PENTIPS 8MM NEEDLE SHORT
- PEN NEEDLE 30G 5MM OUTER
- PEN NEEDLE 30G 8MM INNER
- PEN NEEDLE 30G X 5/16"
- PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2"
- PEN NEEDLES 12MM 29G 29GX12MM,STRL
- PEN NEEDLES 4MM 32G
- PEN NEEDLES 6MM 31G 31GX6MM, STRL
- PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT (OTC)
- PENTIPS PEN NEEDLE 29G 1/2"
- PENTIPS PEN NEEDLE 31G 1/4"
- PENTIPS PEN NEEDLE 31GX3/16" MINI, 5MM
- PENTIPS PEN NEEDLE 31GX5/16" SHORT, 8MM
- PENTIPS PEN NEEDLE 32G 1/4"
- PENTIPS PEN NEEDLE 32GX5/32" 4MM
- PIP PEN NEEDLE 31G X 5MM
- PIP PEN NEEDLE 32G X 4MM
- PREVENT PEN NEEDLE 31GX1/4"
- PREVENT PEN NEEDLE 31GX5/16"
- PRO COMFORT 0.5 ML 30GX1/2"

- PRO COMFORT 0.5 ML 30GX5/16"
- PRO COMFORT 0.5 ML 31GX5/16"
- PRO COMFORT 1 ML 30GX1/2"
- PRO COMFORT 1 ML 30GX5/16"
- PRO COMFORT 1 ML 31GX5/16"
- PRO COMFORT ALCOHOL 70% PADS
- PRO COMFORT PEN NDL 31GX5/16"
- PRO COMFORT PEN NDL 32G X 1/4"
- PRO COMFORT PEN NDL 4MM 32G
- PRO COMFORT PEN NDL 5MM 32G
- PRODIGY INS SYR 1 ML 28GX1/2"
- PRODIGY SYRNG 0.5 ML 31GX5/16"
- PRODIGY SYRNGE 0.3 ML 31GX5/16"
- PURE CMFT SFTY PEN NDL 31G 5MM
- PURE CMFT SFTY PEN NDL 31G 6MM
- PURE CMFT SFTY PEN NDL 32G 4MM
- PURE COMFORT ALCOHOL 70% PADS
- PURE COMFORT PEN NDL 32G 4MM
- PURE COMFORT PEN NDL 32G 5MM
- PURE COMFORT PEN NDL 32G 6MM
- PURE COMFORT PEN NDL 32G 8MM
- RAYA SURE PEN NEEDLE 29G 12MM
- RAYA SURE PEN NEEDLE 31G 4MM
- RAYA SURE PEN NEEDLE 31G 5MM
- RAYA SURE PEN NEEDLE 31G 6MM
- RELI-ON INSULIN 0.5 ML SYR
- RELI-ON INSULIN 1 ML SYR
- RELION INS SYR 0.3 ML 31GX6MM
- RELION INS SYR 0.5 ML 31GX6MM
- RELION INS SYR 1 ML 31GX15/64"
- RELION MINI PEN 31G X 1/4" NDL
- RELION NEEDLES
- RELION PEN NEEDLES
- SAFESNAP INS SYR UNITS-100 0.3 ML 30GX5/16",10X10
- SAFESNAP INS SYR UNITS-100 0.5 ML 29GX1/2",10X10
- SAFESNAP INS SYR UNITS-100 0.5 ML 30GX5/16",10X10
- SAFESNAP INS SYR UNITS-100 1 ML 28GX1/2",10X10
- SAFESNAP INS SYR UNITS-100 1 ML 29GX1/2",10X10
- SAFETY PEN NEEDLE 31G 4MM
- SAFETY PEN NEEDLE 5MM X 31G
- SAFETY SYRINGE 0.5 ML 30G 1/2"
- SECURESAFE PEN NDL 30GX5/16" OUTER
- SECURESAFE SYR 0.5 ML 29G 1/2" OUTER
- SECURESAFE SYRNG 1 ML 29G 1/2" OUTER
- SKY SAFETY PEN NEEDLE 30G 5MM
- SKY SAFETY PEN NEEDLE 30G 8MM
- SM ULT CFT 0.3 ML 31GX5/16(1/2)
- STERILE PADS 2" X 2"
- SURE CMFT SFTY PEN NDL 31G 6MM
- SURE CMFT SFTY PEN NDL 32G 4MM
- SURE COMFORT 0.5 ML SYRINGE
- SURE COMFORT 1 ML SYRINGE
- SURE COMFORT 3/10 ML SYRINGE
- SURE COMFORT 3/10 ML SYRINGE INSULIN SYRINGE
- SURE COMFORT 30G PEN NEEDLE
- SURE COMFORT ALCOHOL PREP PADS
- SURE COMFORT INS 0.3 ML 31GX1/4
- SURE COMFORT INS 0.5 ML 31GX1/4
- SURE COMFORT INS 1 ML 31GX1/4"
- SURE COMFORT PEN NDL 29GX1/2" 12.7MM
- SURE COMFORT PEN NDL 31G 5MM
- SURE COMFORT PEN NDL 31G 8MM
- SURE COMFORT PEN NDL 32G 4MM
- SURE COMFORT PEN NDL 32G 6MM
- SURE-FINE PEN NEEDLES 12.7MM
- SURE-FINE PEN NEEDLES 5MM
- SURE-FINE PEN NEEDLES 8MM
- SURE-JECT INSU SYR U100 0.3 ML
- SURE-JECT INSU SYR U100 0.5 ML
- SURE-JECT INSU SYR U100 1 ML
- SURE-JECT INSUL SYR U100 1 ML
- SURE-JECT INSULIN SYRINGE 1 ML
- SURE-PREP ALCOHOL PREP PADS
- TECHLITE 0.3 ML 29GX12MM (1/2)
- TECHLITE 0.3 ML 30GX12MM (1/2)
- TECHLITE 0.3 ML 30GX8MM (1/2)
- TECHLITE 0.3 ML 31GX6MM (1/2)
- TECHLITE 0.3 ML 31GX8MM (1/2)
- TECHLITE 0.5 ML 29GX12MM (1/2)
- TECHLITE 0.5 ML 30GX12MM (1/2)

- TECHLITE 0.5 ML 30GX8MM (1/2)
- TECHLITE 0.5 ML 31GX6MM (1/2)
- TECHLITE 0.5 ML 31GX8MM (1/2)
- TECHLITE INS SYR 1 ML 29GX12MM
- TECHLITE INS SYR 1 ML 30GX12MM
- TECHLITE INS SYR 1 ML 30GX8MM
- TECHLITE INS SYR 1 ML 31GX6MM
- TECHLITE INS SYR 1 ML 31GX8MM
- TECHLITE PEN NEEDLE 29GX1/2"
- TECHLITE PEN NEEDLE 29GX3/8"
- TECHLITE PEN NEEDLE 31GX1/4"
- TECHLITE PEN NEEDLE 31GX3/16"
- TECHLITE PEN NEEDLE 31GX5/16"
- TECHLITE PEN NEEDLE 32GX1/4"
- TECHLITE PEN NEEDLE 32GX5/16"
- TECHLITE PEN NEEDLE 32GX5/32"
- TECHLITE PLUS PEN NDL 32G 4MM
- TERUMO INS SYRINGE U100-1 ML
- TERUMO INS SYRINGE U100-1/2 ML
- TERUMO INS SYRINGE U100-1/3 ML
- TERUMO INS SYRNG U100-1/2 ML
- THINPRO INS SYRIN U100-0.3 ML
- THINPRO INS SYRIN U100-0.5 ML
- THINPRO INS SYRIN U100-1 ML
- TOPCARE CLICKFINE 31G X 1/4"
- TOPCARE CLICKFINE 31G X 5/16"
- TOPCARE ULTRA COMFORT SYRINGE
- TRUE CMFRT PRO 0.5 ML 30G 5/16"
- TRUE CMFRT PRO 0.5 ML 31G 5/16"
- TRUE CMFRT PRO 0.5 ML 32G 5/16"
- TRUE CMFT SFTY PEN NDL 31G 5MM
- TRUE CMFT SFTY PEN NDL 31G 6MM
- TRUE CMFT SFTY PEN NDL 32G 4MM
- TRUE COMFORT 0.5 ML 30G 1/2"
- TRUE COMFORT 0.5 ML 30G 5/16"
- TRUE COMFORT 0.5 ML 31G 5/16"
- TRUE COMFORT 0.5 ML 31GX5/16"
- TRUE COMFORT 1 ML 31GX5/16"
- TRUE COMFORT ALCOHOL 70% PADS
- TRUE COMFORT PEN NDL 31G 8MM
- TRUE COMFORT PEN NDL 31GX5MM
- TRUE COMFORT PEN NDL 31GX6MM
- TRUE COMFORT PEN NDL 32G 5MM
- TRUE COMFORT PEN NDL 32G 6MM
- TRUE COMFORT PEN NDL 32GX4MM
- TRUE COMFORT PEN NDL 33G 4MM
- TRUE COMFORT PEN NDL 33G 5MM
- TRUE COMFORT PEN NDL 33G 6MM
- TRUE COMFORT PRO 1 ML 30G 1/2"
- TRUE COMFORT PRO 1 ML 30G 5/16"
- TRUE COMFORT PRO 1 ML 31G 5/16"
- TRUE COMFORT PRO 1 ML 32G 5/16"
- TRUE COMFORT PRO ALCOHOL PADS
- TRUE COMFORT SFTY 1 ML 30G 1/2"
- TRUE COMFRT PRO 0.5 ML 30G 1/2"
- TRUE COMFRT SFTY 1 ML 30G 5/16"
- TRUE COMFRT SFTY 1 ML 31G 5/16"
- TRUE COMFRT SFTY 1 ML 32G 5/16"
- TRUEPLUS PEN NEEDLE 29G 12MM
- TRUEPLUS PEN NEEDLE 31G 5MM
- TRUEPLUS PEN NEEDLE 31G 8MM
- TRUEPLUS PEN NEEDLE 31G X 1/4"
- TRUEPLUS PEN NEEDLE 32GX5/32"
- TRUEPLUS SYR 0.3 ML 29GX1/2"
- TRUEPLUS SYR 0.3 ML 30GX5/16"
- TRUEPLUS SYR 0.3 ML 31GX5/16"
- TRUEPLUS SYR 0.5 ML 28GX1/2"
- TRUEPLUS SYR 0.5 ML 29GX1/2"
- TRUEPLUS SYR 0.5 ML 30GX5/16"
- TRUEPLUS SYR 0.5 ML 31GX5/16"
- TRUEPLUS SYR 1 ML 28GX1/2"
- TRUEPLUS SYR 1 ML 29GX1/2"
- TRUEPLUS SYR 1 ML 30GX5/16"
- TRUEPLUS SYR 1 ML 31GX5/16"
- ULTICAR INS 0.3 ML 31GX1/4(1/2)
- ULTICARE INS 1 ML 31GX1/4"
- ULTICARE INS SYR 0.3 ML 30G 8MM
- ULTICARE INS SYR 0.3 ML 31G 6MM
- ULTICARE INS SYR 0.3 ML 31G 8MM
- ULTICARE INS SYR 0.5 ML 31G 6MM
- ULTICARE INS SYR 1 ML 30GX1/2"
- ULTICARE PEN NEEDLE 31GX3/16"
- ULTICARE PEN NEEDLE 6MM 31G
- ULTICARE PEN NEEDLE 8MM 31G
- ULTICARE PEN NEEDLES 12MM 29G



- ULTICARE PEN NEEDLES 4MM 32G MICRO, 32GX4MM
- ULTICARE PEN NEEDLES 6MM 32G
- ULTICARE SAFE PEN NDL 30G 8MM
- ULTICARE SAFE PEN NDL 5MM 30G
- ULTICARE SYR 0.3 ML 29G 12.7MM
- ULTICARE SYR 0.3 ML 30GX1/2"
- ULTICARE SYR 0.3 ML 31GX5/16" SHORT NDL
- ULTICARE SYR 0.5 ML 30GX1/2"
- ULTICARE SYR 0.5 ML 31GX5/16" SHORT NDL
- ULTICARE SYR 1 ML 31GX5/16"
- ULTIGUARD SAFE 1 ML 30G 12.7MM
- ULTIGUARD SAFE PACK 32G 4MM
- ULTIGUARD SAFE0.3 ML 30G 12.7MM
- ULTIGUARD SAFE0.5 ML 30G 12.7MM
- ULTIGUARD SAFEPACK 1 ML 31G 8MM
- ULTIGUARD SAFEPACK 29G 12.7MM
- ULTIGUARD SAFEPACK 31G 5MM
- ULTIGUARD SAFEPACK 31G 6MM
- ULTIGUARD SAFEPACK 31G 8MM
- ULTIGUARD SAFEPACK 32G 6MM
- ULTIGUARD SAFEPK 0.3 ML 31G 8MM
- ULTIGUARD SAFEPK 0.5 ML 31G 8MM
- ULTILET ALCOHOL STERL SWAB
- ULTILET INSULIN SYRINGE 0.3 ML
- ULTILET INSULIN SYRINGE 0.5 ML
- ULTILET INSULIN SYRINGE 1 ML
- ULTILET PEN NEEDLE
- ULTILET PEN NEEDLE 4MM 32G
- ULTRA COMFORT 0.3 ML SYRINGE
- ULTRA COMFORT 0.5 ML 28GX1/2" CONVERTS TO 29G
- ULTRA COMFORT 0.5 ML 29GX1/2"
- ULTRA COMFORT 0.5 ML SYRINGE
- ULTRA COMFORT 1 ML 31GX5/16"
- ULTRA COMFORT 1 ML SYRINGE
- ULTRA FLO 0.3 ML 30G 1/2" (1/2)
- ULTRA FLO 0.3 ML 30G 5/16"(1/2)
- ULTRA FLO 0.3 ML 31G 5/16"(1/2)
- ULTRA FLO PEN NEEDLE 31G 5MM
- ULTRA FLO PEN NEEDLE 31G 8MM
- ULTRA FLO PEN NEEDLE 32G 4MM
- ULTRA FLO PEN NEEDLE 33G 4MM
- ULTRA FLO PEN NEEDLES 12MM 29G
- ULTRA FLO SYR 0.3 ML 29GX1/2"
- ULTRA FLO SYR 0.3 ML 30G 5/16"
- ULTRA FLO SYR 0.3 ML 31G 5/16"
- ULTRA FLO SYR 0.5 ML 29G 1/2"
- ULTRA THIN PEN NDL 32G X 4MM
- ULTRA-THIN II 1 ML 31GX5/16"
- ULTRA-THIN II INS 0.3 ML 30G
- ULTRA-THIN II INS 0.3 ML 31G
- ULTRA-THIN II INS 0.5 ML 29G
- ULTRA-THIN II INS 0.5 ML 30G
- ULTRA-THIN II INS 0.5 ML 31G
- ULTRA-THIN II INS SYR 1 ML 29G
- ULTRA-THIN II INS SYR 1 ML 30G
- ULTRA-THIN II PEN NDL 29GX1/2"
- ULTRA-THIN II PEN NDL 31GX5/16"
- ULTRACARE INS 0.3 ML 30GX5/16"
- ULTRACARE INS 0.3 ML 31GX5/16"
- ULTRACARE INS 0.5 ML 30GX1/2"
- ULTRACARE INS 0.5 ML 30GX5/16"
- ULTRACARE INS 0.5 ML 31GX5/16"
- ULTRACARE INS 1 ML 30G X 5/16"
- ULTRACARE INS 1 ML 30GX1/2"
- ULTRACARE INS 1 ML 31G X 5/16"
- ULTRACARE PEN NEEDLE 31GX1/4"
- ULTRACARE PEN NEEDLE 31GX3/16"
- ULTRACARE PEN NEEDLE 31GX5/16"
- ULTRACARE PEN NEEDLE 32GX1/4"
- ULTRACARE PEN NEEDLE 32GX3/16"
- ULTRACARE PEN NEEDLE 32GX5/32"
- ULTRACARE PEN NEEDLE 33GX5/32"
- UNIFINE PEN NEEDLE 32G 4MM
- UNIFINE PENTIPS 12MM 29G 29GX12MM, STRL
- UNIFINE PENTIPS 31GX3/16" 31GX5MM,STRL,MINI
- UNIFINE PENTIPS 32GX1/4"
- UNIFINE PENTIPS 32GX5/32" 32GX4MM, STRL, NANO
- UNIFINE PENTIPS 33GX5/32"
- UNIFINE PENTIPS 6MM 31G

- UNIFINE PENTIPS MAX 30GX3/16"
- UNIFINE PENTIPS NEEDLES 29G
- UNIFINE PENTIPS PLUS 29GX1/2" 12MM
- UNIFINE PENTIPS PLUS 30GX3/16"
- UNIFINE PENTIPS PLUS 31GX1/4" ULTRA SHORT, 6MM
- UNIFINE PENTIPS PLUS 31GX3/16" MINI
- UNIFINE PENTIPS PLUS 31GX5/16" SHORT
- UNIFINE PENTIPS PLUS 32GX5/32"
- UNIFINE PENTIPS PLUS 33GX5/32"
- UNIFINE PROTECT 30G 5MM
- UNIFINE PROTECT 30G 8MM
- UNIFINE PROTECT 32G 4MM
- UNIFINE SAFECONTROL 30GX3/16"
- UNIFINE SAFECONTROL 30GX5/16"
- UNIFINE SAFECONTROL 31G 5MM
- UNIFINE SAFECONTROL 31G 6MM
- UNIFINE SAFECONTROL 31G 8MM
- UNIFINE SAFECONTROL 32G 4MM
- UNIFINE ULTRA PEN NDL 31G 5MM
- UNIFINE ULTRA PEN NDL 31G 6MM
- UNIFINE ULTRA PEN NDL 31G 8MM
- UNIFINE ULTRA PEN NDL 32G 4MM
- VANISHPOINT 0.5 ML 30GX1/2" SY OUTER
- VANISHPOINT INS 1 ML 30GX3/16"
- VANISHPOINT U-100 29X1/2 SYR
- VERIFINE INS SYR 1 ML 29G 1/2"
- VERIFINE PEN NEEDLE 29G 12MM
- VERIFINE PEN NEEDLE 31G 5MM
- VERIFINE PEN NEEDLE 31G X 6MM
- VERIFINE PEN NEEDLE 31G X 8MM
- VERIFINE PEN NEEDLE 32G 6MM
- VERIFINE PEN NEEDLE 32G X 4MM
- VERIFINE PEN NEEDLE 32G X 5MM
- VERIFINE PLUS PEN NDL 31G 5MM
- VERIFINE PLUS PEN NDL 31G 8MM
- VERIFINE PLUS PEN NDL 32G 4MM
- VERIFINE PLUS PEN NDL 32G 4MM-SHARPS CONTAINER
- VERIFINE SYRING 0.5 ML 29G 1/2"
- VERIFINE SYRING 1 ML 31G 5/16"
- VERIFINE SYRNG 0.3 ML 31G 5/16"
- VERIFINE SYRNG 0.5 ML 31G 5/16"
- VERSALON ALL PURPOSE SPONGE 25'S,N-STERILE,3PLY
- WEBCOL ALCOHOL PREPS 20'S,LARGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	LIFETIME
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# INTERFERON BETA-1A

## Products Affected

- PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML
- PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML
- REBIF (WITH ALBUMIN)
- REBIF REBIDOSE
- REBIF TITRATION PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: Aubagio and glatiramer.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INVEGA HAFYERA

---

## Products Affected

- INVEGA HAFYERA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: oral paliperidone and Invega Sustenna.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INVEGA SUSTENNA

---

## Products Affected

- INVEGA SUSTENNA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: oral paliperidone.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INVEGA TRINZA

---

## Products Affected

- INVEGA TRINZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: oral paliperidone and Invega Sustenna.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ITRACONAZOLE

---

## Products Affected

- *itraconazole oral solution*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# JYLAMVO

---

## Products Affected

- JYLAMVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Oncologist, Dermatologist, Hematologist , Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KALYDECO

---

## Products Affected

- KALYDECO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KERENDIA

## Products Affected

- KERENDIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with a strong CYP3A4 inhibitor or diagnosis of adrenal insufficiency
<b>Required Medical Information</b>	Labs within the past 30 days documenting serum potassium level of less than or equal to 5.0 mEq/L, estimated glomerular filtration rate of at least 25 mL/min/1.73m <sup>2</sup> and urine albumin-to-creatinine ratio (UACR) of at least 30 mg/g (2) Receiving concurrent therapy with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB) at maximally tolerated labeled dosage, unless contraindicated (3) medical justification that a sodium-glucose cotransport-2 (SGLT2) inhibitor (Jardiance, Invokana, Farxiga, Steglatro) AND a steroidal mineralocorticoid receptor antagonist (spironolactone, eplerenone) have been tried and failed, are contraindicated, or would not be medically appropriate for the patient.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KINERET

---

## Products Affected

- KINERET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Rheumatoid Arthritis: Failure or clinically significant adverse effects to two of the formulary alternatives: Enbrel, Humira, Rinvoq, or Xeljanz IR/XR.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KORLYM

## Products Affected

- KORLYM
- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use of simvastatin, lovastatin and CYP3A substrates with narrow therapeutic ranges (e.g. cyclosporine, fentanyl, sirolimus, etc.). History of unexplained vaginal bleeding or endometrial hyperplasia with atypia or endometrial carcinoma.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LEDIPASVIR-SOFOSBUVIR

## Products Affected

- *ledipasvir-sofosbuvir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of chronic hepatitis C infection confirmed by a detectable serum hepatitis C virus RNA through quantitative assay. Documentation of genotype. Documentation of the absence or presence of cirrhosis and if compensated or decompensated. Documentation of any previous treatment. Documentation of liver transplant status. Treatment regimen will be approved based on genotype and previous treatment experience as defined by current AASLD guidelines.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Hepatologist, Infectious Disease specialist
<b>Coverage Duration</b>	Duration will be applied consistent with current AASLD/IDSA guidance.
<b>Other Criteria</b>	Hepatitis C: Failure or clinically significant adverse effects to the formulary alternative: sofosbuvir-velpatasvir (generic Epclusa).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LEUKINE

---

## Products Affected

- LEUKINE INJECTION RECON SOLN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Excessive leukemia myeloid blasts in the bone marrow or peripheral blood equal to or greater than 10%.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, Oncologist
<b>Coverage Duration</b>	3 months.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to formulary alternative: Nivestym and Zarxio.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LEUPROLIDE ACETATE

---

## Products Affected

- *leuprolide (3 month)*
- *leuprolide subcutaneous kit*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Oncologist, Urologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Subject to Part B vs Part D determination.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



# LEVALBUTEROL

## Products Affected

- *levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination. Failure or clinically significant adverse effects to the formulary alternative: albuterol inhalant solution.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LIDOCAINE PATCH

## Products Affected

- *lidocaine topical adhesive patch, medicated 5 %*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of one of the following: Pain associated with diabetic neuropathy, Pain associated with cancer-related neuropathy, Post-herpetic neuralgia, Chronic back pain, or Osteoarthritis of the knee or hip.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LIVTENCITY

---

## Products Affected

- LIVTENCITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	New: Documentation that patient is refractory to prior therapy with ganciclovir, valganciclovir, cidofovir or foscarnet.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Oncologist, Transplant specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LUPRON DEPOT

## Products Affected

- LUPRON DEPOT
- LUPRON DEPOT (3 MONTH)
- LUPRON DEPOT (4 MONTH)
- LUPRON DEPOT (6 MONTH)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Endometriosis: Patient has had surgical ablation to prevent recurrence, or history of failure, contraindication, or intolerance to oral contraceptives.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LYRICA

## Products Affected

- *pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg*
- *pregabalin oral solution*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Postherpetic neuralgia: Failure or clinically significant adverse effects to the formulary alternative: gabapentin. Diabetic neuropathy: Failure or clinically significant adverse effects to all of the formulary alternatives: duloxetine and gabapentin. Fibromyalgia: Failure or clinically significant adverse effects to two of the formulary alternatives: duloxetine, gabapentin or Savella.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# MEGESTROL

## Products Affected

- *megestrol oral suspension 400 mg/10 ml (40 mg/ml)*
- *megestrol oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Cachexia associated with AIDS: Failure or clinically significant adverse effects to all of the formulary alternatives: dronabinol and oxandrolone.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# MEPROBAMATE

## Products Affected

- *meprobamate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to at least two of the formulary alternatives: buspirone, duloxetine, escitalopram, or venlafaxine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# METHOCARBAMOL

---

## Products Affected

- *methocarbamol oral tablet 500 mg, 750 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Documentation explaining specific benefit established with the medication, and how that benefit outweighs the potential risk
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# METHYLDOPA/HYDROCHLOROTHIAZIDE

## Products Affected

- *methyldopa-hydrochlorothiazide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: benazepril, fosinopril, hydrochlorothiazide, irbesartan, lisinopril, losartan, losartan/hydrochlorothiazide, lisinopril/hydrochlorothiazide, quinapril/hydrochlorothiazide, quinapril, ramipril, or valsartan/hydrochlorothiazide.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# METYROSINE

---

## Products Affected

- *metyrosine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Essential hypertension.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# MODAFINIL

---

## Products Affected

- *modafinil*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Narcolepsy: Failure or clinically significant adverse effects to all of the formulary alternatives: dextroamphetamine and methylphenidate.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# NAYZILAM

---

**Products Affected**

- LIBERVANT
- NAYZILAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NIVESTYM

---

## Products Affected

- NIVESTYM INJECTION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, Infectious Disease specialist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUCALA

## Products Affected

- NUCALA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Allergist, Immunologist, Pulmonologist, Rheumatologist, Hematologist, or Otolaryngologist.
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Asthma: Failure or clinically significant adverse effects to two of the formulary alternatives: 1) budesonide, Flovent, Arnuity Ellipta or Qvar and 2) fluticasone-salmeterol, Wixela, or Breo Ellipta.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUEDEXTA

---

## Products Affected

- NUEDEXTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUPLAZID

---

## Products Affected

- NUPLAZID

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# OCTREOTIDE

---

## Products Affected

- *octreotide acetate injection solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# OFEV

---

## Products Affected

- OFEV

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Moderate or severe hepatic impairment (Child-Pugh B or C).
<b>Required Medical Information</b>	Initial authorization: Documentation of liver function tests. Reauthorization only: Documentation of positive response to therapy and documentation of liver function tests.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OLANZAPINE ODT

---

## Products Affected

- *olanzapine oral tablet, disintegrating*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of difficulty or inability to swallow or failure or clinically significant adverse effects to the formulary alternative: oral olanzapine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OLANZAPINE SOLUTION

---

## Products Affected

- *olanzapine intramuscular*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# OMNITROPE

## Products Affected

- OMNITROPE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	AGHD (initial): diagnosis confirmed as a result of past diagnosis of childhood-onset GHD, or adult-onset GHD with documentation of hormone deficiency due to hypothalamic-pituitary disease from organic or known causes (eg: damage from surgery, cranial irradiation, head trauma, subarachnoid hemorrhage) and documentation of one growth-hormone stimulant test (eg: insulin tolerance test, arginine/GHRH, glucagon, arginine) to confirm adult GHD w/corresponding peak GH values ([ITT at or below 5mcg/L],[GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2],[glucagon at or below 3mcg/L],[Arg at or below 0.4mcg/L]) or documented deficiency of 3 anterior pituitary hormones (prolactin, ACTH, TSH, FSH/LH) and IFG-1/somatomedin C below age and gender adjusted normal range as provided by physicians lab. AGHD (reauthorization): Documentation of positive experience by the patient.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORAL ANTIPSYCHOTICS

## Products Affected

- *asenapine maleate*
- CAPLYTA
- COBENFY
- COBENFY STARTER PACK
- FANAPT
- LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG
- *lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg*
- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAPSULE,DOSE PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, quetiapine, risperidone, ziprasidone or aripiprazole.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORENCIA

## Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Rheumatologist, transplant specialist
Coverage Duration	Until the end of calendar year.
Other Criteria	Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# ORKAMBI

---

## Products Affected

- ORKAMBI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of homozygous F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# OTEZLA

---

## Products Affected

- OTEZLA
- OTEZLA STARTER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Plaque psoriasis: documentation of psoriasis with BSA of 2% or greater or affecting crucial body areas such as hands, feet, face or genitals.
Age Restrictions	
Prescriber Restrictions	Dermatologist, Rheumatologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# OXBRYTA

## Products Affected

- OXBRYTA ORAL TABLET 300 MG, 500 MG
- OXBRYTA ORAL TABLET FOR SUSPENSION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of at least 1 episode of vaso-occlusive crisis (VOC) in the past 12 months. Hemoglobin (Hgb) greater than or equal to 5.5 and less than or equal to 10.5 g/dL. Re-authorization: Documentation of positive response to therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OXERVATE

---

## Products Affected

- OXERVATE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of Stage 2 or 3 neurotrophic keratitis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Ophthalmologist
<b>Coverage Duration</b>	8 weeks.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OXTELLAR

## Products Affected

- *oxcarbazepine oral tablet extended release 24 hr 150 mg, 300 mg, 600 mg*
- OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 300 MG, 600 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to oxcarbazepine immediate release.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# PAH

---

## Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Cardiologist, Pulmonologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to the formulary alternative: sildenafil or tadalafil. Approve if in combination with tadalafil for treatment naive PAH patients with WHO FC II and III.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# PARATHYROID HORMONE ANALOGS

## Products Affected

- *teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml)*
- TYMLOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Bone mineral density (BMD) T score of -3.5 or less based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) OR BMD T-score between -2.5 and -3.5 (BMD T-score greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) and a history of fractures.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to one of the formulary alternatives: alendronic acid or risedronate. Medical justification required for treatment duration beyond 24 months.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PDE5 INHIBITORS

## Products Affected

- *alyq*
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*
- TADLIQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with nitrates or PDE5 inhibitors.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Cardiologist, Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PEGFILGRASTIM

## Products Affected

- FULPHILA
- UDENYCA
- UDENYCA AUTOINJECTOR
- UDENYCA ONBODY
- ZIEXTENZO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, Infectious Disease specialist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to formulary alternative: Nivestym and Zarxio.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# PHENOBARBITAL

## Products Affected

- *phenobarbital*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Anticonvulsant: Failure or clinically significant adverse effects to two of the formulary alternatives: carbamazepine, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, tiagabine, topiramate, or zonisamide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PIMECROLIMUS

## Products Affected

- *pimecrolimus*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to one of the topical formulary alternatives: clobetasol, betamethasone, fluocinolone or fluocinonide and failure or clinically significant adverse effects to the formulary alternative: tacrolimus ointment.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# POSACONAZOLE

## Products Affected

- NOXAFIL ORAL SUSPENSION
- *posaconazole oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to one of the formulary alternatives: fluconazole, itraconazole, or voriconazole.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# PRADAXA PELLETT

## Products Affected

- PRADAXA ORAL PELLETS IN PACKET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Pediatric patients aged 3 months to less than 12 years of age.
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# PREMARIN TABLETS

## Products Affected

- PREMARIN ORAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Postmenopausal osteoporosis prophylaxis: Failure or clinically significant adverse effects to all of the formulary alternatives: alendronic acid and risedronate. Vulvar and vaginal atrophy: Failure or clinically significant adverse effects to the formulary alternative: estradiol cream. Other indication(s): Failure or clinically significant adverse effects to one of the formulary alternatives: estradiol transdermal patch or estradiol tablet.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PREMPRO TABLETS

## Products Affected

- PREMPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Postmenopausal osteoporosis prophylaxis: Failure or clinically significant adverse effects to all of the formulary alternatives: alendronic acid and risedronate. Vulvar and vaginal atrophy: Failure or clinically significant adverse effects to the formulary alternative: estradiol cream. Other indication(s): Failure or clinically significant adverse effects to one of the formulary alternatives: estradiol transdermal patch or estradiol tablet.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# PREVYMIS

---

## Products Affected

- PREVYMIS ORAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Oncologist, Transplant specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROCRIT

## Products Affected

- PROCRIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Uncontrolled hypertension.
<b>Required Medical Information</b>	For anemia due to chronic kidney disease: Hemoglobin (Hgb) is less than 10g/dL and documentation of transferrin saturation greater than or equal to 20% and ferritin greater than or equal to 100ng/mL. For anemia due to chemotherapy: Hemoglobin (Hgb) is less than 10g/dL. For surgical FDA indications: Hemoglobin (Hgb) is 10g/dL-13g/dL and patient is not a candidate for autologous blood donation and significant blood loss is anticipated from elective, non cardiac, or nonvascular surgery. Zidovudine induced: Hemoglobin (Hgb) is less than 11g/dL. Myelodysplastic syndrome: Hemoglobin (Hgb) is less than 11g/dL and erythropoietin is less than or equal to 500 mU/mL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# PROLASTIN C

## Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Clinical evidence of emphysema
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year
<b>Other Criteria</b>	Pre-treatment serum levels of alpha-1 antitrypsin (AAT) that is less than 11 micromol/L (80 mg/dl by radial immunodiffusion or 50 mg/dl by nephelometry)
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROLIA

## Products Affected

- PROLIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of bone mineral density (BMD) T-score of -3.5 or less based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) OR BMD T-score between -2.5 and -3.5 (greater than -3.5 and less than or equal to -2.5) based on BMD measurements from lumbar spine (at least two vertebral bodies), hip (femoral neck, total hip), or radius (one-third radius site) and a history of fractures.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to all of the formulary alternatives: alendronic acid and risedronate.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROMACTA

## Products Affected

- PROMACTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of platelet count. Thrombocytopenia in hepatitis C infection: Documentation of concurrent or planned interferon-based treatment of chronic hepatitis C.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Hematologist, Hepatologist, Infectious Disease specialist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Chronic immune (idiopathic) thrombocytopenia: Failure or clinically significant adverse effects to one of the formulary alternatives: dexamethasone, methylprednisolone, prednisolone or prednisone.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROMETHAZINE

## Products Affected

- *promethazine oral*
- *promethazine rectal suppository 12.5 mg, 25 mg*
- *promethegan rectal suppository 25 mg, 50 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Allergy: Failure or clinically significant adverse effects to one of the formulary alternatives: cetirizine and levocetirizine. Nausea and vomiting: Failure or clinically significant adverse effects to two of the formulary alternatives: chlorpromazine, granisetron, ondansetron, or prochlorperazine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROTRIPTYLINE

## Products Affected

- *protriptyline*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PYRIMETHAMINE

## Products Affected

- *pyrimethamine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Anemia due to folate deficiency
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, HIV specialist, Infectious Disease specialist, Oncologist, Transplant specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Primary prophylaxis of toxoplasmic encephalitis: Failure or clinically significant adverse effects to the formulary alternative: trimethoprim/sulfamethoxazole.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# QUININE

---

## Products Affected

- *quinine sulfate*

PA Criteria	Criteria Details
Exclusion Criteria	Prevention or treatment of nocturnal leg cramps.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	10 days.
Other Criteria	Failure or clinically significant adverse effects to one of the formulary alternatives: chloroquine or hydroxychloroquine.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# REPATHA

## Products Affected

- REPATHA PUSHTRONEX
- REPATHA SURECLICK
- REPATHA SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Primary hyperlipidemia: Documentation of current LDL levels above 100mg/dL while taking maximally tolerated statin therapy and ezetimibe therapy, unless intolerant or contraindicated to statin or ezetimibe therapy. Secondary prevention of ASCVD: Documentation of at least one high risk feature: recent ACS (within the past 12 months), history of MI, history of ischemic stroke, or symptomatic peripheral arterial disease (history of claudication with ABI greater than 0.85, or previous revascularization or amputation). Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH): Documentation to confirm diagnosis by genetic testing or by clinical criteria (such as Simon Broome or the Dutch Lipid Clinic Network criteria, or history of untreated LDL-C greater than 180 mg/dL together with xanthoma or cornealis), or evidence of Familial Hypercholesterolemia in first or second-degree relatives.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Cardiologist, Endocrinologist, Lipid specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# RETACRIT

## Products Affected

- RETACRIT INJECTION SOLUTION 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 10,000 UNIT/ML, 2,000 UNIT/ML, 40,000 UNIT/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Uncontrolled hypertension.
<b>Required Medical Information</b>	For anemia due to chronic kidney disease: Hemoglobin (Hgb) is less than 10g/dL and documentation of transferrin saturation greater than or equal to 20% and ferritin greater than or equal to 100ng/mL. For anemia due to chemotherapy: Hemoglobin (Hgb) is less than 10g/dL. For surgical FDA indications: Hemoglobin (Hgb) is 10g/dL-13g/dL and patient is not a candidate for autologous blood donation and significant blood loss is anticipated from elective, non cardiac, or nonvascular surgery. Zidovudine induced: Hemoglobin (Hgb) is less than 11g/dL. Myelodysplastic syndrome: Hemoglobin (Hgb) is less than 11g/dL and erythropoietin is less than or equal to 500 mU/mL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# REXULTI

## Products Affected

- REXULTI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Schizophrenia: Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, risperidone, quetiapine, ziprasidone or aripiprazole. Depression: Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, or venlafaxine.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# REZUROCK

---

## Products Affected

- REZUROCK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RINVOQ

## Products Affected

- RINVOQ LQ
- RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Rheumatologist, dermatologist, gastroenterologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	<p>Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.</p> <p>Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Non-radiographic Axial Spondyloarthritis: Failure or clinically significant adverse effects to a non-steroidal anti-inflammatory drug (NSAID) or has an intolerance or contraindication to NSAID. Crohn's disease and Ulcerative colitis: Failure or clinically significant adverse effects to one of the formulary alternatives: budesonide, mesalamine or sulfasalazine.</p> <p>Initial Atopic Dermatitis: 1) Atopic Dermatitis covering at least 10 percent of body surface area or Atopic Dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas, 2) intractable pruritus or cracking/oozing/bleeding of affected skin, 3) trial of or contraindication to one topical (corticosteroid or calcineurin inhibitor), and 4) no concurrent use with other systemic biologic for Atopic Dermatitis. Renewal: Atopic Dermatitis: 1) improvement while on therapy, and 2) no concurrent use with other systemic biologic for Atopic Dermatitis.</p>
<b>Indications</b>	All FDA-approved Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RISPERDAL CONSTA

## Products Affected

- RISPERDAL CONSTA
- *risperidone microspheres*
- UZEDY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to the formulary alternative: oral risperidone.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# RUFINAMIDE

## Products Affected

- *rufinamide oral suspension*
- *rufinamide oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Failure or clinically significant adverse effects to one of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, clobazam or zonisamide. For Rufinamide suspension: Failure or clinically significant adverse effects to one of the formulary alternatives: Rufinamide tablet.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SAPROPTERIN

---

## Products Affected

- *sapropterin*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# SECUADO

---

## Products Affected

- SECUADO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: olanzapine, quetiapine, risperidone, ziprasidone or aripiprazole.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SIGNIFOR

---

## Products Affected

- SIGNIFOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SIRTURO

---

## Products Affected

- SIRTURO ORAL TABLET 100 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SKYRIZI

## Products Affected

- SKYRIZI SUBCUTANEOUS PEN INJECTOR
- SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, gastroenterologist, rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Plaque psoriasis: Failure or clinically significant adverse effects to one of the following: acitretin, cyclosporine, methotrexate or phototherapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SOFOSBUVIR-VELPATASVIR

## Products Affected

- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of chronic hepatitis C infection confirmed by a detectable serum hepatitis C virus RNA through quantitative assay. Documentation of genotype. Documentation of the absence or presence of cirrhosis and if compensated or decompensated. Documentation of any previous treatment. Documentation of liver transplant status. Treatment regimen will be approved based on genotype and previous treatment experience as defined by current AASLD guidelines.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Hepatologist, Infectious Disease specialist
<b>Coverage Duration</b>	Duration will be applied consistent with current AASLD/IDSA guidance.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SOMAVERT

---

## Products Affected

- SOMAVERT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Endocrinologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: octreotide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SPRITAM

---

## Products Affected

- SPRITAM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: levetiracetam oral solution.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# STELARA

## Products Affected

- STELARA SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Gastroenterologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy. Crohn's disease and Ulcerative colitis: Failure or clinically significant adverse effects to one of the formulary alternatives: budesonide, mesalamine or sulfasalazine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# SYMPAZAN

---

## Products Affected

- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of difficulty or inability to swallow.
Age Restrictions	
Prescriber Restrictions	Neurologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, lorazepam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid or zonisamide.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# SYNAREL

---

## Products Affected

- SYNAREL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TACROLIMUS OINTMENT

## Products Affected

- *tacrolimus topical*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the topical formulary alternatives: clobetasol, betamethasone, fluocinolone, or fluocinonide.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# TADALAFIL

---

## Products Affected

- *tadalafil oral tablet 5 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Erectile Dysfunction without diagnosis of Benign Prostatic Hyperplasia (BPH).
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Benign Prostatic Hyperplasia: 1) trial of one alpha blocker (e.g., doxazosin, terazosin, tamsulosin, alfuzosin), and 2) trial of one 5-alpha-reductase inhibitor (e.g., finasteride, dutasteride).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TAKHZYRO

---

## Products Affected

- TAKHZYRO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of hereditary angioedema (HAE), must be confirmed by blood testing.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Allergist, Immunologist, Hematologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TALTZ

## Products Affected

- TALTZ AUTOINJECTOR
- TALTZ SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Plaque psoriasis: documentation of psoriasis of greater than 3% BSA or affecting crucial body areas such as hands, feet, face or genitals.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ankylosing spondylitis: Failure or clinically significant adverse effects to one of the formulary alternatives: celecoxib, diclofenac, indomethacin, naproxen, or sulindac. Plaque psoriasis: Failure or clinically significant adverse effects to one of the formulary alternatives: acitretin, cyclosporine, methotrexate or phototherapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TARGRETIN

## Products Affected

- *bexarotene*
- TARGRETIN TOPICAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Dermatologist, Oncologist
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# TAVNEOS

## Products Affected

- TAVNEOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	1) Diagnosis of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) variant of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, 2) positive test for either anti-PR3 or anti-MPO, 3) at least 1 major item, 3 non-major items, or 2 renal items of proteinuria and hematuria on the Birmingham Vasculitis Activity Score (BVAS), 4) eGFR greater than or equal to 15 mL/min/1.72 m <sup>2</sup> , 5) currently receiving standard therapy with cyclophosphamide or rituximab
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Rheumatologist, Nephrologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# TAZORAC

## Products Affected

- *tazarotene topical cream*
- *tazarotene topical gel*
- TAZORAC TOPICAL CREAM 0.05 %
- TAZORAC TOPICAL GEL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Plaque psoriasis: Failure or clinically significant adverse effects to one of the topical formulary alternatives: calcipotriene, clobetasol or fluocinonide. Acne vulgaris: Failure or clinically significant adverse effects to two of the formulary alternatives: benzoyl peroxide/clindamycin topical, benzoyl peroxide/erythromycin topical, clindamycin topical, doxycycline oral, erythromycin topical, minocycline oral, tetracycline oral or tretinoin topical.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TECFIDERA

---

## Products Affected

- *dimethyl fumarate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to all of the formulary alternatives: Aubagio and glatiramer.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# TESTOSTERONE

## Products Affected

- *methyltestosterone oral capsule*
- *testosterone cypionate*
- *testosterone enanthate*
- *testosterone transdermal gel in metered-dose pump*
- *testosterone transdermal gel in packet*
- *testosterone transdermal solution in metered pump w/app*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented pretreatment serum testosterone levels less than the laboratory's lower reference limit within the recent 3 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TESTOSTERONE PUMP

## Products Affected

- *testosterone transdermal gel in metered-dose pump*
- *testosterone transdermal gel in packet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented pretreatment serum testosterone levels less than the laboratory's lower reference limit within the recent 3 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: testosterone cypionate, testosterone enanthate or testosterone transdermal gel or solution.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TETRABENAZINE

---

## Products Affected

- *tetrabenazine*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with an MAOI. Untreated or inadequately-treated depression, or current suicidality.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Neurologist
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# TIGECYCLINE

---

## Products Affected

- *tigecycline*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TOBI PODHALER

---

## Products Affected

- TOBI PODHALER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Infectious Disease specialist, Pulmonologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TOBRAMYCIN SOLUTION

---

## Products Affected

- *tobramycin in 0.225 % nacl*
- *tobramycin inhalation*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	Infectious Disease specialist, Pulmonologist
Coverage Duration	Until the end of calendar year.
Other Criteria	Subject to Part B vs Part D determination.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



# TOLCAPONE

---

## Products Affected

- *tolcapone*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of concurrent use with levodopa and carbidopa.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: amantadine, bromocriptine, carbidopa/levodopa, entacapone, pramipexole, ropinirole, or selegiline.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TRELSTAR

---

## Products Affected

- TRELSTAR INTRAMUSCULAR  
SUSPENSION FOR RECONSTITUTION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TRIENTINE

---

## Products Affected

- *trientine oral capsule 250 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Biliary cirrhosis, rheumatoid arthritis.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the formulary alternative: penicillamine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TRIHXYPHENIDYL

## Products Affected

- *trihexyphenidyl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Narrow angle glaucoma.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Parkinsonism: Failure or clinically significant adverse effects to one of the formulary alternatives: amantadine, bromocriptine, carbidopa/levodopa, entacapone, pramipexole, ropinirole, or selegiline. Medication-induced movement disorder - extrapyramidal disease: Failure or clinically significant adverse effects to the formulary alternative: amantadine.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TRIMIPRAMINE

## Products Affected

- *trimipramine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	Approve if less than 65 years of age. If aged 65 years and older, prior authorization criteria will apply.
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# TRINTELLIX

---

## Products Affected

- TRINTELLIX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# UBRELVY

## Products Affected

- UBRELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Medical justification specifying that TWO formulary anti-migraine drugs from different classes have been tried and failed are contraindicated, or would not be medically appropriate. Classes include: (1) Analgesics- aspirin, naproxen, ibuprofen, diclofenac, celecoxib, indomethacin, nabumetone, and (2) Triptans- sumatriptan, rizatriptan/rizatriptan ODT
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Neurologist, Pain Specialist, Headache Specialist
<b>Coverage Duration</b>	Until the end of calendar year
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VALCHLOR

---

## Products Affected

- VALCHLOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Dermatologist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# VANCOMYCIN CAPSULE

---

## Products Affected

- *vancomycin oral capsule 125 mg, 250 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	C diff diarrhea: Reauthorization: Documentation of C. Difficile positive stool
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VEMLIDY

---

## Products Affected

- VEMLIDY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hepatologist, Gastroenterologist, Infectious Disease specialist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VEOZAH

## Products Affected

- VEOZAH

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Menopausal vasomotor symptoms (VMS): initial: 1) experiences 7 or more hot flashes per day, and 2) trial of or contraindication to hormonal therapy (e.g., estradiol transdermal patch, oral conjugated estrogens). Renewal: 1) continued need for VMS treatment (i.e., persistent hot flashes), and 2) reduction in VMS frequency or severity due to Veozah treatment.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VERQUVO

---

## Products Affected

- VERQUVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Cardiologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VIBERZI

---

## Products Affected

- VIBERZI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	History of gallbladder removal.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to the all of the formulary alternatives: dicyclomine and loperamide.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VIIBRYD

---

## Products Affected

- VIIBRYD ORAL TABLET
- *vilazodone*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Failure or clinically significant adverse effects to two of the formulary alternatives: citalopram, escitalopram, fluoxetine, sertraline, venlafaxine, desvenlafaxine, duloxetine, mirtazapine, or bupropion
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# VORICONAZOLE

---

## Products Affected

- *voriconazole intravenous*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# VOWST

## Products Affected

- VOWST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	1) Diagnosis of greater than or equal to 2 recurrent Clostridioides Difficile Infection (CDI), 2) current episode of CDI must be controlled (less than 3 unformed/loose stools/day for 2 consecutive days) following 10 to 21 days of antibiotic therapy, 3) recent positive stool test for C. difficile, and 4) completion of antibiotic treatment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# WEGOVY

## Products Affected

- WEGOVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent use with DPP4 inhibitors, history of Type 1 or Type 2 Diabetes Mellitus, and/or history of NYHA Class IV Heart Failure. Use of weight loss only.
<b>Required Medical Information</b>	BMI greater than or equal to 27 kg/m <sup>2</sup> . Documentation of one of the following: prior MI, prior stroke, symptomatic PAD (evidenced by intermittent claudication with ABI less than 0.85 at rest and/or peripheral arterial revascularization procedure and/or amputation due to ASCVD).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Reauthorization only: Documentation of positive response to medication therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XATMEP

---

## Products Affected

- XATMEP

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Oncologist, Pediatrician, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Subject to Part B vs Part D determination.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XDEMVY

---

## Products Affected

- XDEMVY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XELJANZ

## Products Affected

- XELJANZ ORAL SOLUTION
- XELJANZ ORAL TABLET
- XELJANZ XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Rheumatologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Rheumatoid Arthritis: Failure or clinically significant adverse effects to one of the formulary alternatives: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine. Psoriatic arthritis: Failure or clinically significant adverse effects to the formulary alternative: methotrexate. Ulcerative colitis: Failure or clinically significant adverse effects to formulary alternative: Humira.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XGEVA

---

## Products Affected

- XGEVA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XIFAXAN

---

## Products Affected

- XIFAXAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Until the end of calendar year.
Other Criteria	Hepatic encephalopathy: Failure or clinically significant adverse effects to the formulary alternative: lactulose. Irritable bowel syndrome with diarrhea: Failure or clinically significant adverse effects to all of the formulary alternative: loperamide. Traveler's diarrhea: Failure or clinically significant adverse effects to one of the formulary alternatives: ciprofloxacin or levofloxacin.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# XOLAIR

---

## Products Affected

- XOLAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Asthma (Initial): Forced expiratory volume in one second or peak expiratory flow less than or equal to 80% of predicted level, or measures of asthma control indicate uncontrolled asthma (eg, Asthma Control Test [ACT] score 19 or less). Baseline (pre-Xolair treatment) serum total IgE level greater than or equal to 30 IU/mL. Positive skin test or in vitro reactivity to a perennial aeroallergen.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Allergist, Dermatologist, Immunologist, Pulmonologist, Otolaryngologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XYREM

---

## Products Affected

- *sodium oxybate*
- XYREM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Daytime excessive sleepiness in patients with narcolepsy: Failure or clinically significant adverse effects to two of the formulary alternatives: dextroamphetamine, methylphenidate, and modafinil.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ZARXIO

---

## Products Affected

- ZARXIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Hematologist, Infectious Disease specialist, Oncologist
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZEPATIER

## Products Affected

- ZEPATIER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of chronic hepatitis C infection confirmed by a detectable serum hepatitis C virus RNA through quantitative assay. Documentation of genotype. Documentation of the absence or presence of cirrhosis and if compensated or decompensated. Documentation of any previous treatment. Documentation of liver transplant status. Treatment regimen will be approved based on genotype and previous treatment experience as defined by current AASLD guidelines. For genotype 1a: Documentation for NS5A polymorphism testing.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Gastroenterologist, Hepatologist, Infectious Disease specialist
<b>Coverage Duration</b>	Duration will be applied consistent with current AASLD/IDSA guidance.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZYPREXA RELPREVV

---

## Products Affected

- ZYPREXA RELPREVV  
INTRAMUSCULAR SUSPENSION FOR  
RECONSTITUTION 210 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented history of receiving oral olanzapine without any clinically significant side effects.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Until the end of calendar year.
<b>Other Criteria</b>	Failure or clinically significant adverse effects to two of the formulary alternatives: Invega Sustenna, Invega Trinza or Risperdal Consta.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

## INDEX

### 1

1ST TIER UNIFINE PENTP 5MM 31G. 73,  
82, 83  
1ST TIER UNIFINE PNTIP 4MM 32G.. 73,  
82, 83  
1ST TIER UNIFINE PNTIP 6MM 31G.. 73,  
82, 83  
1ST TIER UNIFINE PNTIP 8MM 31G  
STRL,SINGLE-USE,SHRT ..... 73, 82, 83  
1ST TIER UNIFINE PNTP 29GX1/2 73, 82,  
83  
1ST TIER UNIFINE PNTP 31GX3/16 ... 73,  
82, 83  
1ST TIER UNIFINE PNTP 32GX5/32 ... 73,  
82, 83

### A

ABELCET..... 1  
ABILIFY ASIMTUFII  
INTRAMUSCULAR  
SUSPENSION,EXTENDED REL  
SYRING 720 MG/2.4 ML, 960 MG/3.2  
ML..... 2  
ABILIFY MAINTENA  
INTRAMUSCULAR  
SUSPENSION,EXTENDED REL  
RECON 300 MG, 400 MG ..... 2  
ABILIFY MAINTENA  
INTRAMUSCULAR  
SUSPENSION,EXTENDED REL  
SYRING..... 2  
abiraterone oral tablet 250 mg, 500 mg ... 15,  
17  
ABOUTTIME PEN NEEDLE 30G X 8MM  
..... 73, 82, 83  
ABOUTTIME PEN NEEDLE 31G X 5MM  
..... 73, 82, 83  
ABOUTTIME PEN NEEDLE 31G X 8MM  
..... 73, 82, 83  
ABOUTTIME PEN NEEDLE 32G X 4MM  
..... 73, 82, 83  
acitretin ..... 3  
ACTIMMUNE..... 4  
adefovir ..... 5

ADVOCATE INS 0.3 ML 30GX5/16 73, 82,  
83  
ADVOCATE INS 0.3 ML 31GX5/16 73, 82,  
83  
ADVOCATE INS 0.5 ML 30GX5/16 73, 82,  
83  
ADVOCATE INS 0.5 ML 31GX5/16 73, 82,  
83  
ADVOCATE INS 1 ML 31GX5/16.. 73, 82,  
83  
ADVOCATE INS SYR 0.3 ML 29GX1/2  
..... 73, 82, 83  
ADVOCATE INS SYR 0.5 ML 29GX1/2  
..... 73, 82, 83  
ADVOCATE INS SYR 1 ML 29GX1/2 . 73,  
82, 83  
ADVOCATE INS SYR 1 ML 30GX5/16 73,  
82, 83  
ADVOCATE PEN NDL 12.7MM 29G... 73,  
82, 83  
ADVOCATE PEN NEEDLE 32G 4MM 73,  
82, 83  
ADVOCATE PEN NEEDLE 4MM 33G 73,  
82, 83  
ADVOCATE PEN NEEDLES 5MM 31G  
..... 73, 82, 83  
ADVOCATE PEN NEEDLES 8MM 31G  
..... 73, 82, 83  
AFINITOR DISPERZ ORAL TABLET  
FOR SUSPENSION 2 MG ..... 15, 17  
AIMOVIG AUTOINJECTOR..... 7  
AKEEGA ..... 15, 17  
ALCOHOL 70% SWABS ..... 73, 82, 83  
ALCOHOL PADS ..... 73, 82, 83  
ALCOHOL PREP SWABS ..... 73, 82, 83  
ALCOHOL WIPES ..... 73, 82, 83  
ALECENSA..... 15, 17  
alose tron..... 8  
ALUNBRIG..... 15, 17  
alyq..... 127  
AMBISOME..... 9  
ambrisentan ..... 125  
amitriptyline..... 10

amitriptyline-chlordiazepoxide oral tablet 12.5-5 mg, 25-10 mg.....	10	AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG.....	15, 17
amoxapine .....	11	<b>B</b>	
amphotericin b .....	12	BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG.....	15, 17
amphotericin b liposome.....	9	BD AUTOSHIELD DUO NDL 5MMX30G .....	73, 82, 83
aprepitant.....	18	BD ECLIPSE 30GX1/2 .....	73, 82, 83
APTIOM ORAL TABLET 200 MG, 400 MG, 600 MG, 800 MG .....	13	BD ECLIPSE NEEDLE 30GX1/2	73, 82, 83
AQINJECT PEN NEEDLE 31G 5MM ...	73, 82, 83	BD INS SYR 0.3 ML 8MMX31G(1/2) ...	73, 82, 83
AQINJECT PEN NEEDLE 32G 4MM ...	73, 82, 83	BD INS SYRINGE 1/2 ML 6MMX31G (ONLY FOR 500 UNIT/ML INSULIN) .....	73, 82, 83
ARCALYST .....	19	BD INS SYRN UF 1 ML 12.7MMX30G NOT FOR RETAIL SALE .....	73, 82, 83
ARIKAYCE.....	20	BD INSULIN SYR 1 ML 25GX1	73, 82, 83
armodafinil.....	21	BD INSULIN SYR 1 ML 25GX5/8 ..	73, 82, 83
asenapine maleate .....	118	BD INSULIN SYR 1 ML 26GX1/2 ..	73, 82, 83
ASSURE ID DUO PRO NDL 31G 5MM	73, 82, 83	BD INSULIN SYR 1 ML 27GX12.7MM	73, 82, 83
ASSURE ID DUO-SHIELD 30GX3/16..	73, 82, 83	BD INSULIN SYR 1 ML 27GX5/8 ..	73, 82, 83
ASSURE ID DUO-SHIELD 30GX5/16..	73, 82, 83	BD INSULIN SYRINGE 1 ML W/O NEEDLE.....	73, 82, 83
ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2 ....	73, 82, 83	BD LUER-LOK SYRINGE 1 ML	73, 82, 83
ASSURE ID PEN NEEDLE 30GX3/16..	73, 82, 83	BD NANO 2 GEN PEN NDL 32G 4MM	73, 82, 83
ASSURE ID PEN NEEDLE 30GX5/16..	73, 82, 83	BD SAFETGLD INS 0.3 ML 29G 13MM .....	73, 82, 83
ASSURE ID PEN NEEDLE 31GX3/16..	73, 82, 83	BD SAFETGLD INS 0.5 ML 13MMX29G .....	73, 82, 83
ASSURE ID PRO PEN NDL 30G 5MM	73, 82, 83	BD SAFETYGLD INS 0.3 ML 31G 8MM .....	73, 82, 83
ASSURE ID SYR 0.5 ML 29GX1/2 .	73, 82, 83	BD SAFETYGLD INS 0.5 ML 30G 8MM .....	73, 82, 83
ASSURE ID SYR 0.5 ML 31GX15/64 ...	73, 82, 83	BD SAFETYGLD INS 1 ML 29G 13MM .....	73, 82, 83
ASSURE ID SYR 1 ML 31GX15/64	73, 82, 83	BD SAFETYGLID INS 1 ML 6MMX31G .....	73, 82, 83
atovaquone .....	22	BD SAFETYGLIDE SYRINGE 27GX5/8 .....	73, 82, 83
AUBAGIO .....	23	BD SAFTYGLD INS 0.3 ML 6MMX31G .....	73, 82, 83
AUGTYRO ORAL CAPSULE 40 MG ...	15, 17		
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG .....	24		
AUVELITY .....	25		

BD SAFTYGLD INS 0.5 ML 29G 13MM .....	73, 82, 83	CAREFINE PEN NEEDLES 6MM 32G. 74, 82, 83	
BD SAFTYGLD INS 0.5 ML 6MMX31G .....	73, 82, 83	CAREFINE PEN NEEDLES 8MM 31G. 74, 82, 83	
BD SINGLE USE SWAB.....	74, 82, 83	CARETOUCH ALCOHOL 70% PREP PAD.....	74, 82, 83
BD UF MICRO PEN NEEDLE 6MMX32G .....	74, 82, 83	CARETOUCH PEN NEEDLE 29G 12MM .....	74, 82, 83
BD UF MINI PEN NEEDLE 5MMX31G74, 82, 83		CARETOUCH PEN NEEDLE 31GX1/4 74, 82, 83	
BD UF NANO PEN NEEDLE 4MMX32G .....	74, 82, 83	CARETOUCH PEN NEEDLE 31GX3/16 .....	74, 82, 83
BD UF ORIG PEN NDL 12.7MMX29G 74, 82, 83		CARETOUCH PEN NEEDLE 31GX5/16 .....	74, 82, 83
BD UF SHORT PEN NEEDLE 8MMX31G .....	74, 82, 83	CARETOUCH PEN NEEDLE 32GX3/16 .....	74, 82, 83
BD VEO INS 0.3 ML 6MMX31G (1/2).. 74, 82, 83		CARETOUCH PEN NEEDLE 32GX5/32 .....	74, 82, 83
BD VEO INS SYRING 1 ML 6MMX31G .....	74, 82, 83	CARETOUCH SYR 0.3 ML 31GX5/16 . 74, 82, 83	
BD VEO INS SYRN 0.3 ML 6MMX31G74, 82, 83		CARETOUCH SYR 0.5 ML 30GX5/16 . 74, 82, 83	
BD VEO INS SYRN 0.5 ML 6MMX31G74, 82, 83		CARETOUCH SYR 0.5 ML 31GX5/16 . 74, 82, 83	
BESREMI .....	15, 17	CARETOUCH SYR 1 ML 28GX5/16 .... 74, 82, 83	
bexarotene .....	167	CARETOUCH SYR 1 ML 29GX5/16 .... 74, 82, 83	
BORDERED GAUZE 2 .....	74, 82, 83	CARETOUCH SYR 1 ML 30GX5/16 .... 74, 82, 83	
BOSULIF .....	15, 17	CARETOUCH SYR 1 ML 31GX5/16 .... 74, 82, 83	
BRAFTOVI.....	15, 17	caspofungin .....	27
BRONCHITOL.....	26	CIMZIA .....	28
BRUKINSA .....	15, 17	CIMZIA POWDER FOR RECONST .....	28
<b>C</b>		CLICKFINE 31G X 5/16.....	74, 82, 83
CABOMETYX .....	15, 17	CLICKFINE PEN NEEDLE 32GX5/32.. 74, 82, 83	
CALQUENCE (ACALABRUTINIB MAL) .....	15, 17	CLICKFINE UNIVERSAL 31G X 1/4 ... 74, 82, 83	
CAPLYTA .....	118	clobazam oral suspension .....	14
CAPRELSA .....	15, 17	clobazam oral tablet .....	14
CAREFINE PEN NEEDLE 12.7MM 29G .....	74, 82, 83	clomipramine .....	29
CAREFINE PEN NEEDLE 4MM 32G ... 74, 82, 83		COBENFY .....	118
CAREFINE PEN NEEDLE 5MM 32G ... 74, 82, 83		COBENFY STARTER PACK .....	118
CAREFINE PEN NEEDLE 6MM 31G ... 74, 82, 83		COMETRIQ.....	15, 17
CAREFINE PEN NEEDLE 8MM 30G ... 74, 82, 83			

COMFORT EZ 0.3 ML 31G 15/64 ... 74, 82, 83  
 COMFORT EZ 0.5 ML 31G 15/64 ... 74, 82, 83  
 COMFORT EZ INS 0.3 ML 30GX1/2.... 74, 82, 83  
 COMFORT EZ INS 0.3 ML 30GX5/16.. 74, 82, 83  
 COMFORT EZ INS 1 ML 31G 15/6474, 82, 83  
 COMFORT EZ INS 1 ML 31GX5/1674, 82, 83  
 COMFORT EZ INSULIN SYR 0.3 ML.. 74, 82, 83  
 COMFORT EZ INSULIN SYR 0.5 ML.. 74, 82, 83  
 COMFORT EZ PEN NEEDLE 12MM 29G ..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 4MM 32G SINGLE USE, MICRO..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 4MM 33G ..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 5MM 31G MINI ..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 5MM 33G ..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 6MM 31G ..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 6MM 32G ..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 6MM 33G ..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 8MM 31G SHORT ..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 8MM 32G ..... 74, 82, 83  
 COMFORT EZ PEN NEEDLES 8MM 33G ..... 74, 82, 83  
 COMFORT EZ PRO PEN ND L 30G 8MM ..... 74, 82, 83  
 COMFORT EZ PRO PEN ND L 31G 4MM ..... 74, 82, 83  
 COMFORT EZ PRO PEN ND L 31G 5MM ..... 74, 82, 83

COMFORT EZ SYR 0.3 ML 29GX1/2... 74, 82, 83  
 COMFORT EZ SYR 0.5 ML 28GX1/2... 74, 82, 83  
 COMFORT EZ SYR 0.5 ML 29GX1/2... 74, 82, 83  
 COMFORT EZ SYR 0.5 ML 30GX1/2... 74, 82, 83  
 COMFORT EZ SYR 1 ML 28GX1/2 74, 82, 83  
 COMFORT EZ SYR 1 ML 29GX1/2 74, 82, 83  
 COMFORT EZ SYR 1 ML 30GX1/2 75, 82, 83  
 COMFORT EZ SYR 1 ML 30GX5/16.... 75, 82, 83  
 COMFORT POINT PEN ND L 31GX1/3 75, 82, 83  
 COMFORT POINT PEN ND L 31GX1/6 75, 82, 83  
 COMFORT TOUCH PEN ND L 31G 4MM ..... 75, 82, 83  
 COMFORT TOUCH PEN ND L 31G 5MM ..... 75, 82, 83  
 COMFORT TOUCH PEN ND L 31G 6MM ..... 75, 82, 83  
 COMFORT TOUCH PEN ND L 31G 8MM ..... 75, 82, 83  
 COMFORT TOUCH PEN ND L 32G 4MM ..... 75, 82, 83  
 COMFORT TOUCH PEN ND L 32G 5MM ..... 75, 82, 83  
 COMFORT TOUCH PEN ND L 32G 6MM ..... 75, 82, 83  
 COMFORT TOUCH PEN ND L 32G 8MM ..... 75, 82, 83  
 COMFORT TOUCH PEN ND L 33G 4MM ..... 75, 82, 83  
 COMFORT TOUCH PEN ND L 33G 6MM ..... 75, 82, 83  
 COMFORT TOUCH PEN ND L 33GX5MM ..... 75, 82, 83  
 COPIKTRA..... 15, 17  
 CORLANOR ORAL SOLUTION..... 31  
 CORLANOR ORAL TABLET ..... 31  
 COSENTYX (2 SYRINGES)..... 32

COSENTYX PEN (2 PENS) .....	32	DROPLET INS 0.5 ML 30GX8MM(1/2)	75, 82, 83
COSENTYX SUBCUTANEOUS		DROPLET INS 0.5 ML 31GX6MM(1/2)	75, 82, 83
SYRINGE 75 MG/0.5 ML.....	32	DROPLET INS 0.5 ML 31GX8MM(1/2)	75, 82, 83
COSENTYX UNOREADY PEN .....	32	DROPLET INS SYR 0.3 ML 30GX6MM	75, 82, 83
COTELLIC .....	15, 17	DROPLET INS SYR 0.3 ML 30GX8MM	75, 82, 83
CURAD GAUZE PADS 2.....	75, 82, 83	DROPLET INS SYR 0.3 ML 31GX6MM	75, 82, 83
CURITY ALCOHOL PREPS 2		DROPLET INS SYR 0.3 ML 31GX8MM	75, 82, 83
PLY,MEDIUM .....	75, 82, 83	DROPLET INS SYR 1 ML 29GX12.5MM	75, 82, 83
CURITY GAUZE SPONGES (12 PLY)-		DROPLET INS SYR 1 ML 30GX12.5MM	75, 82, 83
200/BAG.....	75, 82, 83	DROPLET INS SYR 1 ML 30GX6MM .	75, 82, 83
CURITY GUAZE PADS 1'S(12 PLY)....	75, 82, 83	DROPLET INS SYR 1 ML 30GX8MM .	75, 82, 83
cyclobenzaprine oral tablet 10 mg, 5 mg..	33	DROPLET INS SYR 1 ML 31GX6MM .	75, 82, 83
<b>D</b>		DROPLET INS SYR 1 ML 31GX8MM .	75, 82, 83
dalfampridine .....	34	DROPLET MICRON 34G X 9/64	75, 82, 83
DALIRESP .....	35	DROPLET PEN NEEDLE 29GX1/2.	75, 82, 83
dasatinib oral tablet 100 mg, 140 mg, 20 mg,		DROPLET PEN NEEDLE 29GX3/8.	75, 82, 83
50 mg, 70 mg, 80 mg .....	15, 17	DROPLET PEN NEEDLE 30GX5/1675,	82, 83
DAURISMO ORAL TABLET 100 MG, 25		DROPLET PEN NEEDLE 31GX1/4.	75, 82, 83
MG .....	15, 17	DROPLET PEN NEEDLE 31GX3/1675,	82, 83
deferasirox oral tablet, dispersible .....	36	DROPLET PEN NEEDLE 31GX5/1675,	82, 83
DERMACEA 2 .....	75, 82, 83	DROPLET PEN NEEDLE 32GX1/4.	75, 82, 83
DERMACEA GAUZE 2.....	75, 82, 83	DROPLET PEN NEEDLE 32GX3/1675,	82, 83
DERMACEA NON-WOVEN 2 ...	75, 82, 83	DROPLET PEN NEEDLE 32GX5/1675,	82, 83
desipramine.....	37		
dexmethylphenidate oral tablet.....	6		
DIACOMIT.....	14		
diazepam intensol.....	38		
diazepam oral solution 5 mg/5 ml (1 mg/ml)			
.....	38		
dimethyl fumarate .....	39, 170		
disopyramide phosphate oral capsule .....	40		
doxepin oral capsule .....	41		
doxepin oral concentrate.....	41		
DRIZALMA SPRINKLE .....	42		
dronabinol .....	43		
DROPLET 0.5 ML 29GX12.5MM(1/2)..	75, 82, 83		
DROPLET 0.5 ML 30GX12.5MM(1/2)..	75, 82, 83		
DROPLET INS 0.3 ML 29GX12.5MM ..	75, 82, 83		
DROPLET INS 0.3 ML 30GX12.5MM ..	75, 82, 83		
DROPLET INS 0.5 ML 30GX6MM(1/2)	75, 82, 83		



DROPLET PEN NEEDLE 32GX5/3275, 82, 83  
DROPSAFE ALCOHOL 70% PREP PADS ..... 75, 82, 83  
DROPSAFE INS SYR 0.3 ML 31G 6MM ..... 75, 82, 83  
DROPSAFE INS SYR 0.3 ML 31G 8MM ..... 75, 82, 83  
DROPSAFE INS SYR 0.5 ML 31G 6MM ..... 75, 82, 83  
DROPSAFE INS SYR 0.5 ML 31G 8MM ..... 75, 82, 83  
DROPSAFE INSUL SYR 1 ML 31G 6MM ..... 75, 82, 83  
DROPSAFE INSUL SYR 1 ML 31G 8MM ..... 75, 82, 83  
DROPSAFE INSULN 1 ML 29G 12.5MM ..... 75, 82, 83  
DROPSAFE PEN NEEDLE 31GX1/4 .... 75, 82, 83  
DROPSAFE PEN NEEDLE 31GX3/16.. 75, 82, 83  
DROPSAFE PEN NEEDLE 31GX5/16.. 75, 82, 83  
droxidopa ..... 44  
DRUG MART ULTRA COMFORT SYR ..... 75, 82, 83  
DUAVEE ..... 52  
DUPIXENT PEN ..... 45, 46  
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML..... 45, 46

**E**  
EASY CMFT SFTY PEN NDL 31G 5MM ..... 75, 82, 83  
EASY CMFT SFTY PEN NDL 31G 6MM ..... 75, 82, 83  
EASY CMFT SFTY PEN NDL 32G 4MM ..... 75, 82, 83  
EASY COMFORT 0.3 ML 31G 1/2.. 75, 82, 83  
EASY COMFORT 0.3 ML 31G 5/16 76, 82, 83  
EASY COMFORT 0.3 ML SYRINGE ... 76, 82, 83

EASY COMFORT 0.5 ML 30GX1/2 76, 82, 83  
EASY COMFORT 0.5 ML 31GX5/16.... 76, 82, 83  
EASY COMFORT 0.5 ML 32GX5/16.... 76, 82, 83  
EASY COMFORT 0.5 ML SYRINGE ... 76, 82, 83  
EASY COMFORT 1 ML 31GX5/16. 76, 82, 83  
EASY COMFORT 1 ML 32GX5/16. 76, 82, 83  
EASY COMFORT ALCOHOL 70% PAD ..... 76, 82, 83  
EASY COMFORT INSULIN 1 ML SYR 76, 82, 83  
EASY COMFORT PEN NDL 31GX1/4 . 76, 82, 83  
EASY COMFORT PEN NDL 31GX3/1676, 82, 83  
EASY COMFORT PEN NDL 31GX5/1676, 82, 83  
EASY COMFORT PEN NDL 32GX5/3276, 82, 83  
EASY COMFORT PEN NDL 33G 4MM76, 82, 83  
EASY COMFORT PEN NDL 33G 5MM76, 82, 83  
EASY COMFORT PEN NDL 33G 6MM76, 82, 83  
EASY COMFORT SYR 1 ML 30GX1/2 76, 82, 83  
EASY GLIDE INS 0.3 ML 31GX6MM.. 76, 82, 83  
EASY GLIDE INS 0.5 ML 31GX6MM.. 76, 82, 83  
EASY GLIDE INS 1 ML 31GX6MM76, 82, 83  
EASY GLIDE PEN NEEDLE 4MM 33G76, 82, 83  
EASY TOUCH 0.3 ML SYR 30GX1/2... 76, 82, 83  
EASY TOUCH 0.5 ML SYR 27GX1/2... 76, 82, 83  
EASY TOUCH 0.5 ML SYR 29GX1/2... 76, 82, 83

EASY TOUCH 0.5 ML SYR 30GX1/2... 76,  
 82, 83  
 EASY TOUCH 0.5 ML SYR 30GX5/16. 76,  
 82, 83  
 EASY TOUCH 1 ML SYR 27GX1/2 76, 82,  
 83  
 EASY TOUCH 1 ML SYR 29GX1/2 76, 82,  
 83  
 EASY TOUCH 1 ML SYR 30GX1/2 76, 82,  
 83  
 EASY TOUCH ALCOHOL 70% PADS  
 GAMMA-STERILIZED..... 76, 82, 83  
 EASY TOUCH FLIPLOK 1 ML 27GX0.5  
 ..... 76, 82, 83  
 EASY TOUCH INSULIN 1 ML 29GX1/2  
 ..... 76, 82, 83  
 EASY TOUCH INSULIN 1 ML 30GX1/2  
 ..... 76, 82, 83  
 EASY TOUCH INSULIN SYR 0.3 ML.. 76,  
 82, 83  
 EASY TOUCH INSULIN SYR 0.5 ML.. 76,  
 82, 83  
 EASY TOUCH INSULIN SYR 1 ML..... 76,  
 82, 83  
 EASY TOUCH INSULIN SYR 1 ML  
 RETRACTABLE..... 76, 82, 83  
 EASY TOUCH INSULN 1 ML 29GX1/276,  
 82, 83  
 EASY TOUCH INSULN 1 ML 30GX1/276,  
 82, 83  
 EASY TOUCH INSULN 1 ML 30GX5/16  
 ..... 76, 82, 83  
 EASY TOUCH INSULN 1 ML 31GX5/16  
 ..... 76, 82, 83  
 EASY TOUCH LUER LOK INSUL 1 ML  
 ..... 76, 82, 83  
 EASY TOUCH PEN NEEDLE 29GX1/2 76,  
 82, 83  
 EASY TOUCH PEN NEEDLE 30GX5/16  
 ..... 76, 82, 83  
 EASY TOUCH PEN NEEDLE 31GX1/4 76,  
 82, 83  
 EASY TOUCH PEN NEEDLE 31GX3/16  
 ..... 76, 82, 83  
 EASY TOUCH PEN NEEDLE 31GX5/16  
 ..... 76, 82, 83  
 EASY TOUCH PEN NEEDLE 32GX1/4 76,  
 82, 83  
 EASY TOUCH PEN NEEDLE 32GX3/16  
 ..... 76, 82, 83  
 EASY TOUCH PEN NEEDLE 32GX5/32  
 ..... 76, 82, 83  
 EASY TOUCH SAF PEN NDL 29G 5MM  
 ..... 76, 82, 83  
 EASY TOUCH SAF PEN NDL 29G 8MM  
 ..... 76, 82, 83  
 EASY TOUCH SAF PEN NDL 30G 5MM  
 ..... 76, 82, 83  
 EASY TOUCH SAF PEN NDL 30G 8MM  
 ..... 76, 82, 83  
 EASY TOUCH SYR 0.5 ML 28G 12.7MM  
 ..... 76, 82, 83  
 EASY TOUCH SYR 0.5 ML 29G 12.7MM  
 ..... 76, 82, 83  
 EASY TOUCH SYR 1 ML 27G 16MM.. 76,  
 82, 83  
 EASY TOUCH SYR 1 ML 28G 12.7MM  
 ..... 76, 82, 83  
 EASY TOUCH SYR 1 ML 29G 12.7MM  
 ..... 76, 82, 83  
 EASY TOUCH UNI-SLIP SYR 1 ML.... 76,  
 82, 83  
 EASYTOUCH SAF PEN NDL 30G 6MM  
 ..... 76, 82, 83  
 ELIGARD ..... 47  
 ELIGARD (3 MONTH)..... 47  
 ELIGARD (4 MONTH)..... 47  
 ELIGARD (6 MONTH)..... 47  
 EMBRACE PEN NEEDLE 29G 12MM . 76,  
 82, 83  
 EMBRACE PEN NEEDLE 30G 5MM ... 76,  
 82, 83  
 EMBRACE PEN NEEDLE 30G 8MM ... 76,  
 82, 83  
 EMBRACE PEN NEEDLE 31G 5MM ... 76,  
 82, 83  
 EMBRACE PEN NEEDLE 31G 6MM ... 76,  
 82, 83  
 EMBRACE PEN NEEDLE 31G 8MM ... 76,  
 82, 83  
 EMBRACE PEN NEEDLE 32G 4MM ... 76,  
 82, 83

EMSAM.....	48	FP INSULIN 1 ML SYRINGE.....	76, 82, 83
ENBREL MINI.....	49	FREESTYLE PREC 0.5 ML 30GX5/16 .	76, 82, 83
ENBREL SUBCUTANEOUS SOLUTION		FREESTYLE PREC 0.5 ML 31GX5/16 .	76, 82, 83
.....	49	FREESTYLE PREC 1 ML 30GX5/16 ....	77, 82, 83
ENBREL SUBCUTANEOUS SYRINGE	49	FREESTYLE PREC 1 ML 31GX5/16 ....	77, 82, 83
ENBREL SURECLICK.....	49	FRUZAQLA ORAL CAPSULE 1 MG, 5	
ENDARI .....	50	MG .....	15, 17
EPIDIOLEX.....	13	FULPHILA .....	128
EQL INSULIN 0.3 ML SYRINGE SHORT		FYCOMPA ORAL SUSPENSION .....	13
NEEDLE .....	76, 82, 83	FYCOMPA ORAL TABLET.....	13
EQL INSULIN 0.5 ML SYRINGE SHORT		<b>G</b>	
NEEDLE .....	76, 82, 83	GAUZE PAD TOPICAL BANDAGE 2 X 2	
EQL INSULIN 1 ML SYRINGE SHORT		.....	77, 82, 83
NEEDLE .....	76, 82, 83	GAVRETO .....	15, 17
ERIVEDGE.....	15, 17	gefitinib.....	15, 17
ERLEADA ORAL TABLET 240 MG, 60		GENOTROPIN .....	57
MG .....	15, 17	GENOTROPIN MINIQUICK .....	57
erlotinib oral tablet 100 mg, 150 mg, 25 mg		GILENYA.....	59
.....	15, 17	GILOTRIF .....	15, 17
ESBRIET ORAL CAPSULE.....	51	glatiramer .....	60
ESBRIET ORAL TABLET 267 MG, 801		glatopa.....	61
MG .....	51	GLEOSTINE.....	15, 17
estradiol oral.....	52	glutamine (sickle cell).....	50
estradiol transdermal patch weekly.....	52	glyburide .....	63
everolimus (antineoplastic) oral tablet	15, 17	glyburide micronized .....	63
everolimus (antineoplastic) oral tablet for		glyburide-metformin oral tablet 1.25-250	
suspension 3 mg, 5 mg.....	15, 17	mg, 2.5-500 mg, 5-500 mg.....	63
EXKIVITY .....	15, 17	GNP ULT C 0.3 ML 29GX1/2 .....	77, 82, 83
<b>F</b>		GNP ULTRA COMFORT 0.5 ML SYR. .	77, 82, 83
FANAPT .....	118	GNP ULTRA COMFORT 1 ML SYRINGE	
fentanyl citrate buccal lozenge on a handle		.....	77, 82, 83
.....	53	GNP ULTRA COMFORT 3/10 ML SYR	77, 82, 83
FETZIMA ORAL CAPSULE,EXT REL		guanfacine oral tablet.....	64
24HR DOSE PACK 20 MG (2)- 40 MG		guanfacine oral tablet extended release 24 hr	
(26).....	54	.....	64
FETZIMA ORAL CAPSULE,EXTENDED		<b>H</b>	
RELEASE 24 HR .....	54	HEALTHWISE INS 0.3 ML 30GX5/16 .	77, 82, 83
FIFTY50 INS 0.5 ML 31GX5/16. .	76, 82, 83	HEALTHWISE INS 0.3 ML 31GX5/16 .	77, 82, 83
FIFTY50 INS SYR 1 ML 31GX5/16 .	76, 82, 83		
83			
FIFTY50 PEN 31G X 3/16.....	76, 82, 83		
fingolimod.....	59		
FINTEPLA.....	14		
FIRMAGON KIT W DILUENT SYRINGE			
.....	56		
FOTIVDA .....	15, 17		

HEALTHWISE INS 0.5 ML 30GX5/16 . 77, 82, 83  
HEALTHWISE INS 0.5 ML 31GX5/16 . 77, 82, 83  
HEALTHWISE INS 1 ML 30GX5/16 .... 77, 82, 83  
HEALTHWISE INS 1 ML 31GX5/16 .... 77, 82, 83  
HEALTHWISE PEN NEEDLE 31G 5MM ..... 77, 82, 83  
HEALTHWISE PEN NEEDLE 31G 8MM ..... 77, 82, 83  
HEALTHWISE PEN NEEDLE 32G 4MM ..... 77, 82, 83  
HEALTHY ACCENTS PENTIP 4MM 32G ..... 77, 82, 83  
HEALTHY ACCENTS PENTIP 5MM 31G ..... 77, 82, 83  
HEALTHY ACCENTS PENTIP 6MM 31G ..... 77, 82, 83  
HEALTHY ACCENTS PENTIP 8MM 31G ..... 77, 82, 83  
HEALTHY ACCENTS PENTIP 12MM 29G ..... 77, 82, 83  
HEB INCONTROL ALCOHOL 70% PADS ..... 77, 82, 83  
HUMIRA PEN..... 66  
HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML ..... 66  
HUMIRA(CF)..... 66  
HUMIRA(CF) PEDI CROHNS STARTER ..... 67  
HUMIRA(CF) PEN ..... 66  
HUMIRA(CF) PEN CROHNS-UC-HS.... 66  
HUMIRA(CF) PEN PEDIATRIC UC..... 67  
HUMIRA(CF) PEN PSOR-UV-ADOL HS ..... 66

**I**  
IBRANCE..... 15, 17  
icatibant..... 55  
ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG..... 15, 17  
IDHIFA ..... 15, 17  
imatinib oral tablet 100 mg, 400 mg... 15, 17  
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG ..... 15, 17  
IMBRUVICA ORAL SUSPENSION. 15, 17  
IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG..... 15, 17  
imipramine hcl ..... 68  
imipramine pamoate..... 68  
IMPAVIDO..... 69  
INCONTROL PEN NEEDLE 12MM 29G ..... 77, 82, 83  
INCONTROL PEN NEEDLE 4MM 32G 77, 82, 83  
INCONTROL PEN NEEDLE 5MM 31G 77, 82, 83  
INCONTROL PEN NEEDLE 6MM 31G 77, 82, 83  
INCONTROL PEN NEEDLE 8MM 31G 77, 82, 83  
INCRELEX..... 70  
indomethacin oral capsule..... 71  
INGREZZA..... 72  
INGREZZA INITIATION PK(TARDIV) 72  
INGREZZA SPRINKLE ..... 72  
INLYTA ORAL TABLET 1 MG, 5 MG. 15, 17  
INQOVI ..... 15, 17  
INREBIC..... 15, 17  
INSULIN SYR 0.3 ML 31GX1/4(1/2) .... 77, 82, 83  
INSULIN SYRIN 0.3 ML 30GX1/2.. 77, 82, 83  
INSULIN SYRIN 0.5 ML 28GX1/2.. 77, 82, 83  
INSULIN SYRIN 0.5 ML 29GX1/2.. 77, 82, 83  
INSULIN SYRIN 0.5 ML 30GX1/2.. 77, 82, 83  
INSULIN SYRIN 0.5 ML 30GX5/16 77, 82, 83  
INSULIN SYRING 0.5 ML 27G 1/2. 77, 82, 83  
INSULIN SYRINGE 0.3 ML ..... 77, 82, 83  
INSULIN SYRINGE 0.3 ML 31GX1/4 .. 77, 82, 83  
INSULIN SYRINGE 0.5 ML ..... 77, 82, 83  
INSULIN SYRINGE 0.5 ML 31GX1/4 .. 77, 82, 83  
INSULIN SYRINGE 1 ML ..... 77, 82, 83

INSULIN SYRINGE 1 ML 27G 1/2 . 77, 82, 83	KENDALL ALCOHOL 70% PREP PAD77, 82, 83
INSULIN SYRINGE 1 ML 28G 1/2 . 77, 82, 83	KERENDIA ..... 91
INSULIN SYRINGE 1 ML 30GX1/2 77, 82, 83	KINERET ..... 92
INSULIN SYRINGE 1 ML 30GX5/16 ... 77, 82, 83	KISQALI FEMARA CO-PACK ..... 15, 17
INSULIN SYRINGE 1 ML 31GX1/4 77, 82, 83	KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3).... 15, 17
INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2..... 77, 82, 83	KORLYM ..... 93
INSUPEN 30G ULTRAFIN NEEDLE ... 77, 82, 83	KOSELUGO ORAL CAPSULE 10 MG, 25 MG ..... 15, 17
INSUPEN 31G ULTRAFIN NEEDLE ... 77, 82, 83	KRAZATI..... 15, 17
INSUPEN 32G 6MM PEN NEEDLE 77, 82, 83	<b>L</b>
INSUPEN 32G 8MM PEN NEEDLE 77, 82, 83	lapatinib..... 15, 17
INSUPEN PEN NEEDLE 29GX12MM.. 77, 82, 83	LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG..... 118
INSUPEN PEN NEEDLE 31GX3/16 77, 82, 83	LAZCLUZE ORAL TABLET 240 MG, 80 MG ..... 15, 17
INSUPEN PEN NEEDLE 32GX4MM.... 77, 82, 83	ledipasvir-sofosbuvir..... 94
INSUPEN PEN NEEDLE 33GX4MM.... 77, 82, 83	lenalidomide..... 15, 17
INVEGA HAFYERA ..... 85	LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)..... 15, 17
INVEGA SUSTENNA ..... 86	LEUKINE INJECTION RECON SOLN.. 95
INVEGA TRINZA..... 87	leuprolide (3 month) ..... 96
IRESSA..... 15, 17	leuprolide subcutaneous kit..... 96
ITOVEBI ORAL TABLET 3 MG, 9 MG 15, 17	levalbuterol hcl inhalation solution for nebulization 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml..... 97
itraconazole oral solution ..... 88	LIBERVANT ..... 108
IV ANTISEPTIC WIPES ..... 77, 82, 83	lidocaine topical adhesive patch,medicated 5 % ..... 98
ivabradine..... 31	LISCO SPONGES 100/BAG..... 77, 82, 83
IWILFIN ..... 15, 17	LITE TOUCH 31GX1/4 ..... 77, 82, 83
<b>J</b>	LITE TOUCH INSULIN 0.5 ML SYR ... 77, 82, 83
JAKAFI..... 15, 17	LITE TOUCH INSULIN 1 ML SYR 77, 82, 83
JAYPIRCA ORAL TABLET 100 MG, 50 MG ..... 15, 17	LITE TOUCH INSULIN SYR 1 ML 77, 82, 83
JYLAMVO ..... 89	LITE TOUCH PEN NEEDLE 29G ... 77, 82, 83
<b>K</b>	
KALYDECO..... 90	

LITE TOUCH PEN NEEDLE 31G ... 77, 82, 83  
LITETOUCH INS 0.3 ML 29GX1/2. 77, 82, 83  
LITETOUCH INS 0.3 ML 30GX5/1677, 82, 83  
LITETOUCH INS 0.3 ML 31GX5/1677, 82, 83  
LITETOUCH INS 0.5 ML 31GX5/1677, 82, 83  
LITETOUCH SYR 0.5 ML 28GX1/2 77, 82, 83  
LITETOUCH SYR 0.5 ML 29GX1/2 77, 82, 83  
LITETOUCH SYR 0.5 ML 30GX5/16 ... 78, 82, 83  
LITETOUCH SYRIN 1 ML 28GX1/2 .... 78, 82, 83  
LITETOUCH SYRIN 1 ML 29GX1/2 .... 78, 82, 83  
LITETOUCH SYRIN 1 ML 30GX5/16 .. 78, 82, 83  
LIVTENCITY ..... 99  
LONSURF ..... 15, 17  
LORBRENA ORAL TABLET 100 MG, 25 MG ..... 15, 17  
LUMAKRAS ORAL TABLET 120 MG, 320 MG ..... 15, 17  
LUPRON DEPOT ..... 100  
LUPRON DEPOT (3 MONTH) ..... 100  
LUPRON DEPOT (4 MONTH) ..... 100  
LUPRON DEPOT (6 MONTH) ..... 100  
lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg ..... 118  
LYNPARZA ..... 16, 17  
LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) ..... 16, 17

**M**  
MAGELLAN INSUL SYRINGE 0.3 ML 78, 82, 83  
MAGELLAN INSUL SYRINGE 0.5 ML 78, 82, 83  
MAGELLAN INSULIN SYR 0.3 ML .... 78, 82, 83

MAGELLAN INSULIN SYR 0.5 ML .... 78, 82, 83  
MAGELLAN INSULIN SYRINGE 1 ML ..... 78, 82, 83  
MATULANE ..... 16, 17  
MAXICOMFORT II PEN NDL 31GX6MM ..... 78, 82, 83  
MAXICOMFORT INS 0.5 ML 27GX1/2 78, 82, 83  
MAXI-COMFORT INS 0.5 ML 28G 78, 82, 83  
MAXICOMFORT INS 1 ML 27GX1/2 .. 78, 82, 83  
MAXI-COMFORT INS 1 ML 28GX1/2. 78, 82, 83  
MAXICOMFORT PEN NDL 29G X 5MM ..... 78, 82, 83  
MAXICOMFORT PEN NDL 29G X 8MM ..... 78, 82, 83  
megestrol oral suspension 400 mg/10 ml (40 mg/ml)..... 102  
megestrol oral tablet..... 102  
MEKINIST ORAL RECON SOLN ... 16, 17  
MEKINIST ORAL TABLET 0.5 MG, 2 MG ..... 16, 17  
MEKTOVI ..... 16, 17  
meprobamate..... 103  
methocarbamol oral tablet 500 mg, 750 mg ..... 104  
methyl dopa-hydrochlorothiazide ..... 105  
methylphenidate hcl oral capsule, er biphasic 30-70 ..... 6  
methylphenidate hcl oral capsule,er biphasic 50-50 ..... 6  
methylphenidate hcl oral solution..... 6  
methylphenidate hcl oral tablet..... 6  
methylphenidate hcl oral tablet extended release ..... 6  
methyltestosterone oral capsule ..... 171  
metyrosine..... 106  
MICRODOT PEN NEEDLE 31GX6MM 78, 82, 83  
MICRODOT PEN NEEDLE 32GX4MM 78, 82, 83  
MICRODOT PEN NEEDLE 33GX4MM 78, 82, 83

MICRODOT READYGARD NDL 31G	
5MM OUTER .....	78, 82, 83
mifepristone oral tablet 300 mg .....	93
MINI PEN NEEDLE 32G 4MM ..	78, 82, 83
MINI PEN NEEDLE 32G 5MM ..	78, 82, 83
MINI PEN NEEDLE 32G 6MM ..	78, 82, 83
MINI PEN NEEDLE 32G 8MM ..	78, 82, 83
MINI PEN NEEDLE 33G 4MM ..	78, 82, 83
MINI PEN NEEDLE 33G 5MM ..	78, 82, 83
MINI PEN NEEDLE 33G 6MM ..	78, 82, 83
MINI ULTRA-THIN II PEN NDL 31G	
STERILE.....	78, 82, 83
modafinil .....	107
molindone oral tablet 10 mg, 25 mg, 5 mg	65
MONOJECT 0.5 ML SYRN 28GX1/2....	78, 82, 83
MONOJECT 1 ML SYRN 27X1/2....	78, 82, 83
MONOJECT 1 ML SYRN 28GX1/2.	78, 82, 83
MONOJECT INSUL SYR U100 (OTC) .	78, 82, 83
MONOJECT INSUL SYR U100	
.5ML,29GX1/2.....	78, 82, 83
MONOJECT INSUL SYR U100 0.5 ML	
CONVERTS TO 29G (OTC)....	78, 82, 83
MONOJECT INSUL SYR U100 1 ML...	78, 82, 83
MONOJECT INSUL SYR U100 1 ML 3'S,	
29GX1/2.....	78, 82, 83
MONOJECT INSUL SYR U100 1 ML W/O	
NEEDLE (OTC) .....	78, 82, 83
MONOJECT INSULIN SYR 0.3 ML	78, 82, 83
MONOJECT INSULIN SYR 0.3 ML (OTC)	
.....	78, 82, 83
MONOJECT INSULIN SYR 0.5 ML	78, 82, 83
MONOJECT INSULIN SYR 0.5 ML (OTC)	
.....	78, 82, 83
MONOJECT INSULIN SYR 1 ML 3'S	
(OTC).....	78, 82, 83
MONOJECT INSULIN SYR U-100 .	78, 82, 83
MONOJECT SYRINGE 0.3 ML..	78, 82, 83
MONOJECT SYRINGE 0.5 ML..	78, 82, 83
MONOJECT SYRINGE 1 ML.....	78, 82, 83
MOTPOLY XR ORAL	
CAPSULE,EXTENDED RELEASE	
24HR 100 MG, 150 MG, 200 MG.....	14
MOUNJARO .....	62
MOVANTIK.....	30
<b>N</b>	
NAYZILAM .....	108
NERLYNX .....	16, 17
NEXAVAR.....	16, 17
NINLARO.....	16, 17
NIVESTYM INJECTION .....	109
NOVOFINE 30 .....	78, 82, 83
NOVOFINE 32G NEEDLES .....	78, 82, 83
NOVOFINE PLUS PEN NDL 32GX1/6.	78, 82, 83
NOVOTWIST NEEDLE 32G 5MM .	78, 82, 83
NOXAFIL ORAL SUSPENSION .....	131
NUBEQA.....	16, 17
NUCALA .....	110
NUEDEXTA.....	111
NUPLAZID.....	112
<b>O</b>	
octreotide acetate injection solution.....	113
ODOMZO .....	16, 17
OFEV .....	114
OGSIVEO ORAL TABLET 100 MG, 150	
MG, 50 MG.....	16, 17
OJEMDA ORAL SUSPENSION FOR	
RECONSTITUTION .....	16, 17
OJEMDA ORAL TABLET .....	16, 17
OJJAARA ORAL TABLET 100 MG, 150	
MG, 200 MG.....	16, 17
olanzapine intramuscular .....	116
olanzapine oral tablet,disintegrating .....	115
OMNITROPE .....	117
ONUREG.....	16, 17
ORENCIA CLICKJECT.....	119
ORENCIA SUBCUTANEOUS SYRINGE	
125 MG/ML, 50 MG/0.4 ML, 87.5	
MG/0.7 ML.....	119
ORGOVYX.....	16, 17
ORKAMBI.....	120
ORSERDU ORAL TABLET 345 MG, 86	
MG .....	16, 17

OTEZLA.....	121	phenobarbital.....	129
OTEZLA STARTER .....	121	pimecrolimus.....	130
OXBRYTA ORAL TABLET 300 MG, 500 MG .....	122	PIP PEN NEEDLE 31G X 5MM..	78, 82, 83
OXBRYTA ORAL TABLET FOR SUSPENSION .....	122	PIP PEN NEEDLE 32G X 4MM..	78, 82, 83
oxcarbazepine oral tablet extended release 24 hr 150 mg, 300 mg, 600 mg.....	124	PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) .....	16, 17
OXERVATE.....	123	pirfenidone oral capsule.....	51
OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 300 MG, 600 MG.....	124	pirfenidone oral tablet 267 mg, 534 mg, 801 mg .....	51
OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) .....	62	PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML .....	84
<b>P</b>		PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML .....	84
PANRETIN.....	16, 17	POMALYST .....	16, 17
pazopanib .....	16, 17	posaconazole oral.....	131
PC UNIFINE PENTIPS 8MM NEEDLE SHORT .....	78, 82, 83	PRADAXA ORAL PELLETS IN PACKET .....	132
PEMAZYRE.....	16, 17	pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg .....	101
PEN NEEDLE 30G 5MM OUTER ...	78, 82, 83	pregabalin oral solution.....	101
PEN NEEDLE 30G 8MM INNER	78, 82, 83	PREMARIN ORAL .....	133
PEN NEEDLE 30G X 5/16.....	78, 82, 83	PREMPRO.....	134
PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2.....	78, 82, 83	PREVENT PEN NEEDLE 31GX1/4.	78, 82, 83
PEN NEEDLES 12MM 29G 29GX12MM,STRL.....	78, 82, 83	PREVENT PEN NEEDLE 31GX5/16	78, 82, 83
PEN NEEDLES 4MM 32G .....	78, 82, 83	PREVYMIS ORAL .....	135
PEN NEEDLES 6MM 31G 31GX6MM, STRL.....	78, 82, 83	PRO COMFORT 0.5 ML 30GX1/2... 78, 82, 83	
PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT (OTC)	78, 82, 83	PRO COMFORT 0.5 ML 30GX5/16.	79, 82, 83
PENTIPS PEN NEEDLE 29G 1/2	78, 82, 83	PRO COMFORT 0.5 ML 31GX5/16.	79, 82, 83
PENTIPS PEN NEEDLE 31G 1/4	78, 82, 83	PRO COMFORT 1 ML 30GX1/2.	79, 82, 83
PENTIPS PEN NEEDLE 31GX3/16.	78, 82, 83	PRO COMFORT 1 ML 30GX5/16....	79, 82, 83
PENTIPS PEN NEEDLE 31GX5/16.	78, 82, 83	PRO COMFORT 1 ML 31GX5/16....	79, 82, 83
PENTIPS PEN NEEDLE 32G 1/4	78, 82, 83	PRO COMFORT ALCOHOL 70% PADS .....	79, 82, 83
PENTIPS PEN NEEDLE 32GX5/32.	78, 82, 83	PRO COMFORT PEN NDL 31GX5/16..	79, 82, 83
perphenazine-amitriptyline .....	10		



PRO COMFORT PEN NDL 32G X 1/4.. 79,  
 82, 83  
 PRO COMFORT PEN NDL 4MM 32G.. 79,  
 82, 83  
 PRO COMFORT PEN NDL 5MM 32G.. 79,  
 82, 83  
 PROCRI... 136  
 PRODIGY INS SYR 1 ML 28GX1/2 79, 82,  
 83  
 PRODIGY SYRNG 0.5 ML 31GX5/16 .. 79,  
 82, 83  
 PRODIGY SYRNGE 0.3 ML 31GX5/16 79,  
 82, 83  
 PROLASTIN-C INTRAVENOUS  
 SOLUTION..... 137  
 PROLIA ..... 138  
 PROMACTA ..... 139  
 promethazine oral..... 140  
 promethazine rectal suppository 12.5 mg, 25  
 mg ..... 140  
 promethegan rectal suppository 25 mg, 50  
 mg ..... 140  
 protriptyline..... 141  
 PURE CMFT SFTY PEN NDL 31G 5MM  
 ..... 79, 82, 83  
 PURE CMFT SFTY PEN NDL 31G 6MM  
 ..... 79, 82, 83  
 PURE CMFT SFTY PEN NDL 32G 4MM  
 ..... 79, 82, 83  
 PURE COMFORT ALCOHOL 70% PADS  
 ..... 79, 82, 83  
 PURE COMFORT PEN NDL 32G 4MM 79,  
 82, 83  
 PURE COMFORT PEN NDL 32G 5MM 79,  
 82, 83  
 PURE COMFORT PEN NDL 32G 6MM 79,  
 82, 83  
 PURE COMFORT PEN NDL 32G 8MM 79,  
 82, 83  
 PURIXAN..... 16, 17  
 pyrimethamine ..... 142  
**Q**  
 QINLOCK..... 16, 17  
 quinine sulfate..... 143

**R**  
 RAYA SURE PEN NEEDLE 29G 12MM  
 ..... 79, 82, 83  
 RAYA SURE PEN NEEDLE 31G 4MM 79,  
 82, 83  
 RAYA SURE PEN NEEDLE 31G 5MM 79,  
 82, 83  
 RAYA SURE PEN NEEDLE 31G 6MM 79,  
 82, 83  
 REBIF (WITH ALBUMIN) ..... 84  
 REBIF REBIDOSE..... 84  
 REBIF TITRATION PACK ..... 84  
 RELION INS SYR 0.3 ML 31GX6MM.. 79,  
 82, 83  
 RELION INS SYR 0.5 ML 31GX6MM.. 79,  
 82, 83  
 RELION INS SYR 1 ML 31GX15/64 79, 82,  
 83  
 RELI-ON INSULIN 0.5 ML SYR 79, 82, 83  
 RELI-ON INSULIN 1 ML SYR... 79, 82, 83  
 RELION MINI PEN 31G X 1/4 ... 79, 82, 83  
 RELION NEEDLES ..... 79, 82, 83  
 RELION PEN NEEDLES..... 79, 82, 83  
 REPATHA PUSHTRONEX..... 144  
 REPATHA SURECLICK..... 144  
 REPATHA SYRINGE..... 144  
 RETACRIT INJECTION SOLUTION  
 10,000 UNIT/ML, 2,000 UNIT/ML,  
 20,000 UNIT/ML, 3,000 UNIT/ML,  
 4,000 UNIT/ML, 40,000 UNIT/ML ... 145  
 RETEVMO ORAL CAPSULE 40 MG, 80  
 MG ..... 16, 17  
 RETEVMO ORAL TABLET 120 MG, 160  
 MG, 40 MG, 80 MG ..... 16, 17  
 REVLIMID ..... 16, 17  
 REXULTI ORAL TABLET ..... 146  
 REZLIDHIA ..... 16, 17  
 REZUROCK..... 147  
 RINVOQ LQ..... 148, 149  
 RINVOQ ORAL TABLET EXTENDED  
 RELEASE 24 HR 15 MG, 30 MG, 45  
 MG ..... 148, 149  
 RISPERDAL CONSTA..... 150  
 risperidone microspheres ..... 150  
 roflumilast..... 35

ROZLYTREK ORAL CAPSULE 100 MG,  
200 MG ..... 16, 17  
ROZLYTREK ORAL PELLETS IN  
PACKET ..... 16, 17  
RUBRACA ..... 16, 17  
rufinamide oral suspension ..... 151  
rufinamide oral tablet ..... 151  
RYBELSUS ..... 62  
RYDAPT ..... 16, 17  
**S**  
SAFESNAP INS SYR UNITS-100 0.3 ML  
30GX5/16..... 79, 82, 83  
SAFESNAP INS SYR UNITS-100 0.5 ML  
29GX1/2..... 79, 82, 83  
SAFESNAP INS SYR UNITS-100 0.5 ML  
30GX5/16..... 79, 82, 83  
SAFESNAP INS SYR UNITS-100 1 ML  
28GX1/2..... 79, 82, 83  
SAFESNAP INS SYR UNITS-100 1 ML  
29GX1/2..... 79, 82, 83  
SAFETY PEN NEEDLE 31G 4MM . 79, 82,  
83  
SAFETY PEN NEEDLE 5MM X 31G ... 79,  
82, 83  
SAFETY SYRINGE 0.5 ML 30G 1/2 79, 82,  
83  
sapropterin..... 152  
SCEMBLIX ORAL TABLET 100 MG, 20  
MG, 40 MG..... 16, 17  
SECUADO..... 153  
SECURESAFE PEN NDL 30GX5/16 79, 82,  
83  
SECURESAFE SYR 0.5 ML 29G 1/2 79, 82,  
83  
SECURESAFE SYRNG 1 ML 29G 1/2.. 79,  
82, 83  
SIGNIFOR ..... 154  
sildenafil (pulm.hypertension) oral tablet 127  
SIRTURO ORAL TABLET 100 MG..... 155  
SKY SAFETY PEN NEEDLE 30G 5MM  
..... 79, 82, 83  
SKY SAFETY PEN NEEDLE 30G 8MM  
..... 79, 82, 83  
SKYRIZI SUBCUTANEOUS PEN  
INJECTOR..... 156

SKYRIZI SUBCUTANEOUS SYRINGE  
150 MG/ML ..... 156  
SKYRIZI SUBCUTANEOUS WEARABLE  
INJECTOR..... 156  
SM ULT CFT 0.3 ML 31GX5/16(1/2).... 79,  
82, 83  
sodium oxybate ..... 200  
sofosbuvir-velpatasvir ..... 157  
SOMAVERT..... 158  
sorafenib..... 16, 17  
SPRITAM ..... 159  
SPRYCEL ORAL TABLET 100 MG, 140  
MG, 20 MG, 50 MG, 70 MG, 80 MG . 16,  
17  
STELARA SUBCUTANEOUS..... 160  
STERILE PADS 2 ..... 79, 82, 83  
STIVARGA ..... 16, 17  
sunitinib malate..... 16, 17  
SURE CMFT SFTY PEN NDL 31G 6MM  
..... 79, 82, 83  
SURE CMFT SFTY PEN NDL 32G 4MM  
..... 79, 82, 83  
SURE COMFORT 0.5 ML SYRINGE.... 79,  
82, 83  
SURE COMFORT 1 ML SYRINGE. 79, 82,  
83  
SURE COMFORT 3/10 ML SYRINGE.. 79,  
82, 83  
SURE COMFORT 3/10 ML SYRINGE  
INSULIN SYRINGE ..... 79, 82, 83  
SURE COMFORT 30G PEN NEEDLE .. 79,  
82, 83  
SURE COMFORT ALCOHOL PREP  
PADS ..... 79, 82, 83  
SURE COMFORT INS 0.3 ML 31GX1/4 79,  
82, 83  
SURE COMFORT INS 0.5 ML 31GX1/4 79,  
82, 83  
SURE COMFORT INS 1 ML 31GX1/4.. 79,  
82, 83  
SURE COMFORT PEN NDL 29GX1/2 . 79,  
82, 83  
SURE COMFORT PEN NDL 31G 5MM 79,  
82, 83  
SURE COMFORT PEN NDL 31G 8MM 79,  
82, 83

SURE COMFORT PEN NDL 32G 4MM 79, 82, 83  
 SURE COMFORT PEN NDL 32G 6MM 79, 82, 83  
 SURE-FINE PEN NEEDLES 12.7MM... 79, 82, 83  
 SURE-FINE PEN NEEDLES 5MM.. 79, 82, 83  
 SURE-FINE PEN NEEDLES 8MM.. 79, 82, 83  
 SURE-JECT INSU SYR U100 0.3 ML... 79, 82, 83  
 SURE-JECT INSU SYR U100 0.5 ML... 79, 82, 83  
 SURE-JECT INSU SYR U100 1 ML 79, 82, 83  
 SURE-JECT INSUL SYR U100 1 ML ... 79, 82, 83  
 SURE-JECT INSULIN SYRINGE 1 ML 79, 82, 83  
 SURE-PREP ALCOHOL PREP PADS .. 79, 82, 83  
 SUTENT ..... 16, 17  
 SYMPAZAN..... 161  
 SYNAREL ..... 162  
**T**  
 TABLOID ..... 16, 17  
 TABRECTA ..... 16, 17  
 tacrolimus topical..... 163  
 tadalafil (pulm. hypertension)..... 127  
 tadalafil oral tablet 5 mg ..... 164  
 TADLIQ..... 127  
 TAFINLAR..... 16, 17  
 TAGRISSO ..... 16, 17  
 TAKHZYRO..... 165  
 TALTZ AUTOINJECTOR..... 166  
 TALTZ SYRINGE..... 166  
 TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG ..... 16, 17  
 TARGRETIN TOPICAL ..... 167  
 TASIGNA ..... 16, 17  
 TAVNEOS ..... 168  
 tazarotene topical cream ..... 169  
 tazarotene topical gel ..... 169  
 TAZORAC TOPICAL CREAM 0.05 % 169

TAZORAC TOPICAL GEL ..... 169  
 TAZVERIK..... 16, 17  
 TECHLITE 0.3 ML 29GX12MM (1/2)... 79, 82, 83  
 TECHLITE 0.3 ML 30GX12MM (1/2)... 79, 82, 83  
 TECHLITE 0.3 ML 30GX8MM (1/2)79, 82, 83  
 TECHLITE 0.3 ML 31GX6MM (1/2)79, 82, 83  
 TECHLITE 0.3 ML 31GX8MM (1/2)79, 82, 83  
 TECHLITE 0.5 ML 29GX12MM (1/2)... 79, 82, 83  
 TECHLITE 0.5 ML 30GX12MM (1/2)... 79, 82, 83  
 TECHLITE 0.5 ML 30GX8MM (1/2)80, 82, 83  
 TECHLITE 0.5 ML 31GX6MM (1/2)80, 82, 83  
 TECHLITE 0.5 ML 31GX8MM (1/2)80, 82, 83  
 TECHLITE INS SYR 1 ML 29GX12MM ..... 80, 82, 83  
 TECHLITE INS SYR 1 ML 30GX12MM ..... 80, 82, 83  
 TECHLITE INS SYR 1 ML 30GX8MM 80, 82, 83  
 TECHLITE INS SYR 1 ML 31GX6MM 80, 82, 83  
 TECHLITE INS SYR 1 ML 31GX8MM 80, 82, 83  
 TECHLITE PEN NEEDLE 29GX1/2 80, 82, 83  
 TECHLITE PEN NEEDLE 29GX3/8 80, 82, 83  
 TECHLITE PEN NEEDLE 31GX1/4 80, 82, 83  
 TECHLITE PEN NEEDLE 31GX3/16 ... 80, 82, 83  
 TECHLITE PEN NEEDLE 31GX5/16 ... 80, 82, 83  
 TECHLITE PEN NEEDLE 32GX1/4 80, 82, 83  
 TECHLITE PEN NEEDLE 32GX5/16 ... 80, 82, 83

TECHLITE PEN NEEDLE 32GX5/32 ... 80, 82, 83  
 TECHLITE PLUS PEN NDL 32G 4MM 80, 82, 83  
 TEPMETKO ..... 16, 17  
 teriflunomide ..... 23  
 teriparatide subcutaneous pen injector 20 mcg/dose (620mcg/2.48ml) ..... 126  
 TERUMO INS SYRINGE U100-1 ML... 80, 82, 83  
 TERUMO INS SYRINGE U100-1/2 ML 80, 82, 83  
 TERUMO INS SYRINGE U100-1/3 ML 80, 82, 83  
 TERUMO INS SYRNG U100-1/2 ML ... 80, 82, 83  
 testosterone cypionate ..... 171  
 testosterone enanthate ..... 171  
 testosterone transdermal gel in metered-dose pump ..... 171, 172  
 testosterone transdermal gel in packet ... 171, 172  
 testosterone transdermal solution in metered pump w/app ..... 171  
 tetrabenazine ..... 173  
 THALOMID ..... 16, 17  
 THINPRO INS SYRIN U100-0.3 ML .... 80, 82, 83  
 THINPRO INS SYRIN U100-0.5 ML .... 80, 82, 83  
 THINPRO INS SYRIN U100-1 ML . 80, 82, 83  
 thioridazine ..... 65  
 TIBSOVO ..... 16, 17  
 tigecycline ..... 174  
 TOBI PODHALER ..... 175  
 tobramycin in 0.225 % nacl ..... 176  
 tobramycin inhalation ..... 176  
 tolcapone ..... 177  
 TOPCARE CLICKFINE 31G X 1/4.. 80, 82, 83  
 TOPCARE CLICKFINE 31G X 5/16 80, 82, 83  
 TOPCARE ULTRA COMFORT SYRINGE ..... 80, 82, 83  
 torpenz ..... 16, 17

TRELSTAR INTRAMUSCULAR  
 SUSPENSION FOR  
 RECONSTITUTION ..... 178  
 trientine oral capsule 250 mg ..... 179  
 trihexyphenidyl ..... 180  
 trimipramine ..... 181  
 TRINTELLIX ..... 182  
 TRUE CMFRT PRO 0.5 ML 30G 5/16... 80, 82, 83  
 TRUE CMFRT PRO 0.5 ML 31G 5/16... 80, 82, 83  
 TRUE CMFRT PRO 0.5 ML 32G 5/16... 80, 82, 83  
 TRUE CMFT SFTY PEN NDL 31G 5MM ..... 80, 82, 83  
 TRUE CMFT SFTY PEN NDL 31G 6MM ..... 80, 82, 83  
 TRUE CMFT SFTY PEN NDL 32G 4MM ..... 80, 82, 83  
 TRUE COMFORT 0.5 ML 30G 1/2.. 80, 82, 83  
 TRUE COMFORT 0.5 ML 30G 5/16 80, 82, 83  
 TRUE COMFORT 0.5 ML 31G 5/16 80, 82, 83  
 TRUE COMFORT 0.5 ML 31GX5/16.... 80, 82, 83  
 TRUE COMFORT 1 ML 31GX5/16. 80, 82, 83  
 TRUE COMFORT ALCOHOL 70% PADS ..... 80, 82, 83  
 TRUE COMFORT PEN NDL 31G 8MM80, 82, 83  
 TRUE COMFORT PEN NDL 31GX5MM ..... 80, 82, 83  
 TRUE COMFORT PEN NDL 31GX6MM ..... 80, 82, 83  
 TRUE COMFORT PEN NDL 32G 5MM80, 82, 83  
 TRUE COMFORT PEN NDL 32G 6MM80, 82, 83  
 TRUE COMFORT PEN NDL 32GX4MM ..... 80, 82, 83  
 TRUE COMFORT PEN NDL 33G 4MM80, 82, 83

TRUE COMFORT PEN NDL 33G 5MM 80, 82, 83  
 TRUE COMFORT PEN NDL 33G 6MM 80, 82, 83  
 TRUE COMFORT PRO 1 ML 30G 1/2.. 80, 82, 83  
 TRUE COMFORT PRO 1 ML 30G 5/16 80, 82, 83  
 TRUE COMFORT PRO 1 ML 31G 5/16 80, 82, 83  
 TRUE COMFORT PRO 1 ML 32G 5/16 80, 82, 83  
 TRUE COMFORT PRO ALCOHOL PADS ..... 80, 82, 83  
 TRUE COMFORT SFTY 1 ML 30G 1/2 80, 82, 83  
 TRUE COMFRT PRO 0.5 ML 30G 1/2.. 80, 82, 83  
 TRUE COMFRT SFTY 1 ML 30G 5/16. 80, 82, 83  
 TRUE COMFRT SFTY 1 ML 31G 5/16. 80, 82, 83  
 TRUE COMFRT SFTY 1 ML 32G 5/16. 80, 82, 83  
 TRUEPLUS PEN NEEDLE 29G 12MM 80, 82, 83  
 TRUEPLUS PEN NEEDLE 31G 5MM .. 80, 82, 83  
 TRUEPLUS PEN NEEDLE 31G 8MM .. 80, 82, 83  
 TRUEPLUS PEN NEEDLE 31G X 1/4 .. 80, 82, 83  
 TRUEPLUS PEN NEEDLE 32GX5/32 .. 80, 82, 83  
 TRUEPLUS SYR 0.3 ML 29GX1/2.. 80, 82, 83  
 TRUEPLUS SYR 0.3 ML 30GX5/16 80, 82, 83  
 TRUEPLUS SYR 0.3 ML 31GX5/16 80, 82, 83  
 TRUEPLUS SYR 0.5 ML 28GX1/2.. 80, 82, 83  
 TRUEPLUS SYR 0.5 ML 29GX1/2.. 80, 82, 83  
 TRUEPLUS SYR 0.5 ML 30GX5/16 80, 82, 83

TRUEPLUS SYR 0.5 ML 31GX5/16 80, 82, 83  
 TRUEPLUS SYR 1 ML 28GX1/2 80, 82, 83  
 TRUEPLUS SYR 1 ML 29GX1/2 80, 82, 83  
 TRUEPLUS SYR 1 ML 30GX5/16... 80, 82, 83  
 TRUEPLUS SYR 1 ML 31GX5/16... 80, 82, 83  
 TRULICITY ..... 62  
 TRUQAP..... 16, 17  
 TUKYSA ORAL TABLET 150 MG, 50 MG ..... 16, 17  
 TURALIO ORAL CAPSULE 125 MG, 200 MG ..... 16, 17  
 TYMLOS ..... 126  
 U  
 UBRELVY ..... 183  
 UDENYCA ..... 128  
 UDENYCA AUTOINJECTOR ..... 128  
 UDENYCA ONBODY ..... 128  
 ULTICAR INS 0.3 ML 31GX1/4(1/2) .... 80, 82, 83  
 ULTICARE INS 1 ML 31GX1/4 . 80, 82, 83  
 ULTICARE INS SYR 0.3 ML 30G 8MM ..... 80, 82, 83  
 ULTICARE INS SYR 0.3 ML 31G 6MM ..... 80, 82, 83  
 ULTICARE INS SYR 0.3 ML 31G 8MM ..... 80, 82, 83  
 ULTICARE INS SYR 0.5 ML 31G 6MM ..... 80, 82, 83  
 ULTICARE INS SYR 1 ML 30GX1/2.... 80, 82, 83  
 ULTICARE PEN NEEDLE 31GX3/16... 80, 82, 83  
 ULTICARE PEN NEEDLE 6MM 31G... 80, 82, 83  
 ULTICARE PEN NEEDLE 8MM 31G... 80, 82, 83  
 ULTICARE PEN NEEDLES 12MM 29G ..... 80, 82, 83  
 ULTICARE PEN NEEDLES 4MM 32G MICRO, 32GX4MM..... 81, 82, 83  
 ULTICARE PEN NEEDLES 6MM 32G 81, 82, 83

ULTICARE SAFE PEN NDL 30G 8MM 81,  
 82, 83  
 ULTICARE SAFE PEN NDL 5MM 30G 81,  
 82, 83  
 ULTICARE SYR 0.3 ML 29G 12.7MM. 81,  
 82, 83  
 ULTICARE SYR 0.3 ML 30GX1/2.. 81, 82,  
 83  
 ULTICARE SYR 0.3 ML 31GX5/16 81, 82,  
 83  
 ULTICARE SYR 0.5 ML 30GX1/2.. 81, 82,  
 83  
 ULTICARE SYR 0.5 ML 31GX5/16 81, 82,  
 83  
 ULTICARE SYR 1 ML 31GX5/16... 81, 82,  
 83  
 ULTIGUARD SAFE 1 ML 30G 12.7MM  
 ..... 81, 82, 83  
 ULTIGUARD SAFE PACK 32G 4MM.. 81,  
 82, 83  
 ULTIGUARD SAFE0.3 ML 30G 12.7MM  
 ..... 81, 82, 83  
 ULTIGUARD SAFE0.5 ML 30G 12.7MM  
 ..... 81, 82, 83  
 ULTIGUARD SAFEPACK 1 ML 31G  
 8MM ..... 81, 82, 83  
 ULTIGUARD SAFEPACK 29G 12.7MM  
 ..... 81, 82, 83  
 ULTIGUARD SAFEPACK 31G 5MM... 81,  
 82, 83  
 ULTIGUARD SAFEPACK 31G 6MM... 81,  
 82, 83  
 ULTIGUARD SAFEPACK 31G 8MM... 81,  
 82, 83  
 ULTIGUARD SAFEPACK 32G 6MM... 81,  
 82, 83  
 ULTIGUARD SAFEPK 0.3 ML 31G 8MM  
 ..... 81, 82, 83  
 ULTIGUARD SAFEPK 0.5 ML 31G 8MM  
 ..... 81, 82, 83  
 ULTILET ALCOHOL STERL SWAB ... 81,  
 82, 83  
 ULTILET INSULIN SYRINGE 0.3 ML. 81,  
 82, 83  
 ULTILET INSULIN SYRINGE 0.5 ML. 81,  
 82, 83

ULTILET INSULIN SYRINGE 1 ML.... 81,  
 82, 83  
 ULTILET PEN NEEDLE ..... 81, 82, 83  
 ULTILET PEN NEEDLE 4MM 32G 81, 82,  
 83  
 ULTRA COMFORT 0.3 ML SYRINGE. 81,  
 82, 83  
 ULTRA COMFORT 0.5 ML 28GX1/2... 81,  
 82, 83  
 ULTRA COMFORT 0.5 ML 29GX1/2... 81,  
 82, 83  
 ULTRA COMFORT 0.5 ML SYRINGE. 81,  
 82, 83  
 ULTRA COMFORT 1 ML 31GX5/16.... 81,  
 82, 83  
 ULTRA COMFORT 1 ML SYRINGE.... 81,  
 82, 83  
 ULTRA FLO 0.3 ML 30G 1/2..... 81, 82, 83  
 ULTRA FLO 0.3 ML 30G 5/16.... 81, 82, 83  
 ULTRA FLO 0.3 ML 31G 5/16.... 81, 82, 83  
 ULTRA FLO PEN NEEDLE 31G 5MM. 81,  
 82, 83  
 ULTRA FLO PEN NEEDLE 31G 8MM. 81,  
 82, 83  
 ULTRA FLO PEN NEEDLE 32G 4MM. 81,  
 82, 83  
 ULTRA FLO PEN NEEDLE 33G 4MM. 81,  
 82, 83  
 ULTRA FLO PEN NEEDLES 12MM 29G  
 ..... 81, 82, 83  
 ULTRA FLO SYR 0.3 ML 29GX1/2 81, 82,  
 83  
 ULTRA FLO SYR 0.3 ML 30G 5/16 81, 82,  
 83  
 ULTRA FLO SYR 0.3 ML 31G 5/16 81, 82,  
 83  
 ULTRA FLO SYR 0.5 ML 29G 1/2.. 81, 82,  
 83  
 ULTRA THIN PEN NDL 32G X 4MM.. 81,  
 82, 83  
 ULTRACARE INS 0.3 ML 30GX5/16 ... 81,  
 82, 83  
 ULTRACARE INS 0.3 ML 31GX5/16 ... 81,  
 82, 83  
 ULTRACARE INS 0.5 ML 30GX1/2 81, 82,  
 83

ULTRACARE INS 0.5 ML 30GX5/16 ... 81, 82, 83  
 ULTRACARE INS 0.5 ML 31GX5/16 ... 81, 82, 83  
 ULTRACARE INS 1 ML 30G X 5/16 .... 81, 82, 83  
 ULTRACARE INS 1 ML 30GX1/2 .. 81, 82, 83  
 ULTRACARE INS 1 ML 31G X 5/16 .... 81, 82, 83  
 ULTRACARE PEN NEEDLE 31GX1/4. 81, 82, 83  
 ULTRACARE PEN NEEDLE 31GX3/1681, 82, 83  
 ULTRACARE PEN NEEDLE 31GX5/1681, 82, 83  
 ULTRACARE PEN NEEDLE 32GX1/4. 81, 82, 83  
 ULTRACARE PEN NEEDLE 32GX3/1681, 82, 83  
 ULTRACARE PEN NEEDLE 32GX5/3281, 82, 83  
 ULTRACARE PEN NEEDLE 33GX5/3281, 82, 83  
 ULTRA-THIN II 1 ML 31GX5/1681, 82, 83  
 ULTRA-THIN II INS 0.3 ML 30G ... 81, 82, 83  
 ULTRA-THIN II INS 0.3 ML 31G ... 81, 82, 83  
 ULTRA-THIN II INS 0.5 ML 29G ... 81, 82, 83  
 ULTRA-THIN II INS 0.5 ML 30G ... 81, 82, 83  
 ULTRA-THIN II INS 0.5 ML 31G ... 81, 82, 83  
 ULTRA-THIN II INS SYR 1 ML 29G.... 81, 82, 83  
 ULTRA-THIN II INS SYR 1 ML 30G.... 81, 82, 83  
 ULTRA-THIN II PEN NDL 29GX1/2 .... 81, 82, 83  
 ULTRA-THIN II PEN NDL 31GX5/16.. 81, 82, 83  
 UNIFINE PEN NEEDLE 32G 4MM 81, 82, 83  
 UNIFINE PENTIPS 12MM 29G  
 29GX12MM, STRL..... 81, 82, 83  
 UNIFINE PENTIPS 31GX3/16.... 81, 82, 83  
 UNIFINE PENTIPS 32GX1/4..... 81, 82, 83  
 UNIFINE PENTIPS 32GX5/32.... 81, 82, 83  
 UNIFINE PENTIPS 33GX5/32.... 81, 82, 83  
 UNIFINE PENTIPS 6MM 31G.... 81, 82, 83  
 UNIFINE PENTIPS MAX 30GX3/16 82, 83  
 UNIFINE PENTIPS NEEDLES 29G . 82, 83  
 UNIFINE PENTIPS PLUS 29GX1/2 . 82, 83  
 UNIFINE PENTIPS PLUS 30GX3/1682, 83  
 UNIFINE PENTIPS PLUS 31GX1/4 . 82, 83  
 UNIFINE PENTIPS PLUS 31GX3/1682, 83  
 UNIFINE PENTIPS PLUS 31GX5/1682, 83  
 UNIFINE PENTIPS PLUS 32GX5/32 82, 83  
 UNIFINE PENTIPS PLUS 33GX5/32 82, 83  
 UNIFINE PROTECT 30G 5MM..... 82, 83  
 UNIFINE PROTECT 30G 8MM..... 82, 83  
 UNIFINE PROTECT 32G 4MM..... 82, 83  
 UNIFINE SAFECONTROL 30GX3/16.. 82, 83  
 UNIFINE SAFECONTROL 30GX5/16.. 82, 83  
 UNIFINE SAFECONTROL 31G 5MM.. 82, 83  
 UNIFINE SAFECONTROL 31G 6MM.. 82, 83  
 UNIFINE SAFECONTROL 31G 8MM.. 82, 83  
 UNIFINE SAFECONTROL 32G 4MM.. 82, 83  
 UNIFINE ULTRA PEN NDL 31G 5MM 82, 83  
 UNIFINE ULTRA PEN NDL 31G 6MM 82, 83  
 UNIFINE ULTRA PEN NDL 31G 8MM 82, 83  
 UNIFINE ULTRA PEN NDL 32G 4MM 82, 83  
 UZEDY ..... 150  
**V**  
 VALCHLOR..... 184  
 vancomycin oral capsule 125 mg, 250 mg  
 ..... 185  
 VANFLYTA..... 16, 17  
 VANISHPOINT 0.5 ML 30GX1/2..... 82, 83

VANISHPOINT INS 1 ML 30GX3/16 ... 82, 83	voriconazole intravenous ..... 191
VANISHPOINT U-100 29X1/2 SYR. 82, 83	VOTRIENT..... 16, 17
VEMLIDY ..... 186	VOWST ..... 192
VENCLEXTA..... 16, 17	VRAYLAR ORAL CAPSULE..... 118
VENCLEXTA STARTING PACK .... 16, 17	VRAYLAR ORAL CAPSULE,DOSE PACK..... 118
VEOZAH ..... 187	<b>W</b>
VERIFINE INS SYR 1 ML 29G 1/2 .. 82, 83	WEBCOL ALCOHOL PREPS
VERIFINE PEN NEEDLE 29G 12MM .. 82, 83	20'S,LARGE ..... 82, 83
VERIFINE PEN NEEDLE 31G 5MM 82, 83	WEGOVY..... 193
VERIFINE PEN NEEDLE 31G X 6MM 82, 83	WELIREG..... 16, 17
VERIFINE PEN NEEDLE 31G X 8MM 82, 83	<b>X</b>
VERIFINE PEN NEEDLE 32G 6MM 82, 83	XALKORI ORAL CAPSULE..... 16, 17
VERIFINE PEN NEEDLE 32G X 4MM 82, 83	XALKORI ORAL PELLETT 150 MG, 20 MG, 50 MG..... 16, 17
VERIFINE PEN NEEDLE 32G X 5MM 82, 83	XATMEP ..... 194
VERIFINE PLUS PEN NDL 31G 5MM. 82, 83	XDEMVY ..... 195
VERIFINE PLUS PEN NDL 31G 8MM. 82, 83	XELJANZ ORAL SOLUTION ..... 196
VERIFINE PLUS PEN NDL 32G 4MM. 82, 83	XELJANZ ORAL TABLET..... 196
VERIFINE PLUS PEN NDL 32G 4MM- SHARPS CONTAINER ..... 82, 83	XELJANZ XR ..... 196
VERIFINE SYRING 0.5 ML 29G 1/2 82, 83	XERMELO ..... 16, 17
VERIFINE SYRING 1 ML 31G 5/16 82, 83	XGEVA..... 197
VERIFINE SYRNG 0.3 ML 31G 5/1682, 83	XIFAXAN..... 198
VERIFINE SYRNG 0.5 ML 31G 5/1682, 83	XOLAIR ..... 199
VERQUVO ..... 188	XOSPATA ..... 16, 17
VERSALON ALL PURPOSE SPONGE 25'S,N-STERILE,3PLY ..... 82, 83	XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK) ..... 17
VERZENIO..... 16, 17	XTANDI..... 17
VIBERZI..... 189	XYREM ..... 200
VIIIBRYD ORAL TABLET..... 190	<b>Y</b>
vilazodone ..... 190	YONSA..... 17
VITRAKVI ORAL CAPSULE 100 MG, 25 MG ..... 16, 17	<b>Z</b>
VITRAKVI ORAL SOLUTION ..... 16, 17	ZARXIO ..... 201
VIZIMPRO ..... 16, 17	ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG..... 17
VONJO ..... 16, 17	ZELBORAF..... 17
VORANIGO ORAL TABLET 10 MG, 40 MG ..... 16, 17	ZEPATIER..... 202
	ZIEXTENZO ..... 128
	ziprasidone mesylate..... 58
	ZOLINZA ..... 17
	ZYDELIG ..... 17



ZYKADIA ..... 17

ZYPREXA RELPREVV  
INTRAMUSCULAR SUSPENSION  
FOR RECONSTITUTION 210 MG... 203